USRE39593E1 - 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects - Google Patents

1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects Download PDF

Info

Publication number
USRE39593E1
USRE39593E1 US10/462,844 US46284403A USRE39593E US RE39593 E1 USRE39593 E1 US RE39593E1 US 46284403 A US46284403 A US 46284403A US RE39593 E USRE39593 E US RE39593E
Authority
US
United States
Prior art keywords
meta
alkyl
para
phenyl
dimethylaminopropane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/462,844
Inventor
Helmut Buschmann
Wolfgang Strassburger
Elmar Friderichs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6524045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=USRE39593(E1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal GmbH filed Critical Gruenenthal GmbH
Priority to US10/462,844 priority Critical patent/USRE39593E1/en
Application granted granted Critical
Publication of USRE39593E1 publication Critical patent/USRE39593E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/48—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups
    • C07C215/54—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/56—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups
    • C07C215/58—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
    • C07C215/62—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by hydroxy groups with hydroxy groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain the chain having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
    • C07C217/62—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
    • C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
    • C07C217/72—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having at least three carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C219/20—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C219/22—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/33—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring
    • C07C323/35—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group
    • C07C323/36—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to a carbon atom of the same non-condensed six-membered aromatic ring the thio group being a sulfide group the sulfur atom of the sulfide group being further bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Definitions

  • the present invention relates to 1-phenyl-3-dimethylaminopropane compounds, to a method of preparing them, and to the use of these substances as pharmaceutical active ingredients.
  • Opioids have been used for many years as analgesics for the treatment of pain, although they give rise to a series of side effects, for example addiction and dependency, respiratory depression, gastrointestinal inhibition and obstipation. They can therefore only be given over an extended period of time or in higher doses subject to special precautionary measures such as special prescription regulations (Goodman, Gilman in “The Pharmacological Basis of Therapeutics”, Pergamon Press, New York (1990)).
  • Tramadol hydrochloride (1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride—assumes a special position amongst centrally-acting analgesics, since this active ingredient gives rise to a pronounced inhibition of pain without the side effects which are known for opioids (J. Pharmacol. Exptl. Ther.4 267, 331 (1993)).
  • Tramadol is a racemate and consists of identical amounts of (+) and ( ⁇ ) enantiomer. In vivo the active ingredient forms the metabolite O-desmethyl-tramadol, which is likewise present as a mixture of enantiomers. Investigations have shown that both the enantiomers of tramadol and the enantiomers of tramadol metabolites contribute to the analgesic effect (J. Pharmacol. Exp. Ther. 260, 275 (1992
  • the underlying object of the present invention was to provide substances with an analgesic effect, which are suitable for the treatment of severe pain without giving rise to the side effects which are typical of opioids.
  • a further object was to provide analgesic substances which do not exhibit the side effects, for example nausea and vomiting, which occur during treatment with tramadol in some cases.
  • the present invention accordingly relates to 1-phenyl-3-dimethylaminopropane compounds of formula I in which
  • 1-phenyl-3-dimethylaminopropane compounds of formula I are preferred in which X constitutes OH, F, Cl or H; R 1 represents a C 1-4 -alkyl group; R 2 represents H or CH 3 , and R 3 represents H or CH 3 , and if R 5 is H, R 4 represents OC 1-3 -alkyl, —OH, —S—C 1-3 -alkyl, F, Cl, CH 3 , —CF 2 H or —CF 3 in the meta-position, or para-CF 3 , or if R5 is a para-Cl or para-F, R 4 represents meta-Cl or meta-F, or R 4 and R 5 together represent 3,4-OCH ⁇ CH—.
  • the present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which the variable X represents OH, which is characterized in that a ⁇ -dimethylaminoketone of formula II is reacted with an organometallic compound of formula III in which Z represents MgCl, MgBr, MgI or Li, to form a compound of formula I in which X represents OH.
  • the reaction of a ⁇ -dimethylaminoketone with a Grignard reagent of formula III, in which Z represents MgCl, MgBr or MgI, or with an organolithium compound of formula III can be carried out in an a liphatic ether, for example diethyl ether and/or tetrahydrofuran, at temperatures between ⁇ 70° C. and +60° C.
  • Organolithium compounds of formula II can be obtained by the replacement of halogen by lithium, for example, by reacting a compound of formula III, in which Z represents Cl, Br or I, with a solution of n-butyllithium in n-hexane.
  • ⁇ -dimethylaminoketones of formula II can be obtained from ketones of general formula IV by reaction with dimethylamine hydrochloride and formaldehyde in glacial acetic acid or in a C 1-4 -alkyl alcohol or by reaction with dimethylammonium ethylene chloride in acetonitrile using acetyl chloride as a catalyst (Synthesis 1973, 703).
  • 1-phenyl-3-dimethylaminopropane compounds of formula I in which R 4 and/or R 5 constitute the OH group, can be prepared from the corresponding 1-(4(5)-methoxyphenyl)-3-dimethylaminopropanol compounds by selective ether cleavage with diisobutylaluminium hydride in an aromatic hydrocarbon, for example toluene, at a temperature between 60 and 130° C. (Synthesis 1975, 617).
  • the present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents H, which is characterized in that a compound of formula I, in which X represents Cl, is reacted with zinc borohydride, zinc cyanoborohydride and/or tin cyanoborohydride.
  • the reaction is usually conducted in a solvent, for example diethyl ether and/or tetrahydrofuran, at a temperature between 0° C. and 30° C.
  • a solvent for example diethyl ether and/or tetrahydrofuran
  • the present invention further relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, where X represents F, which is characterized in that a compound of formula I, in which X represents OH, is reacted with dimethylaminosulfur trifluoride in a solvent.
  • Suitable solvents include dichloromethane, 1,1,2-trichloroethane and/or toluene.
  • the reaction is usually conducted at a temperature between ⁇ 50° C. and +30° C. (Org. React. 35, 513 (1988)). If a compound of formula I with X ⁇ OH is used in which R 4 and/or R 5 constitute OH groups, these OH groups must be protected before reaction with the fluorine compound, for example by reaction with benzoyl chloride.
  • the present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents Cl, which is characterized in that a compound of formula I, in which X represents OH, is reacted with thionyl chloride.
  • the reaction is usually conducted in the absence of solvent at a temperature between 0° C. and 20° C. Replacement of OH by Cl is effected while maintaining the configuration.
  • the present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents an OCOR 6 group where R 6 is a C 1-3 -alkyl, which is characterized in that a compound of formula I, in which X represents OH, is reacted with an acid chloride Cl—COOR 6 .
  • the reaction is preferably conducted in a solvent, for example dichloromethane, toluene and/or tetrahydrofuran, at a temperature between ⁇ 10° C. and +30° C.
  • a solvent for example dichloromethane, toluene and/or tetrahydrofuran
  • 1-phenyl-3-dimethylaminopropane compounds of formula I in which R 5 is H and R 4 is a meta-phosphate group, meta-carbonate group, meta-carbamate group or meta-carboxylate group, can be obtained by the reaction of the corresponding 1-(3-hydroxyphenyl)-3-dimethylaminopropane compounds of formula I in the form of their alkali salts with an alkali salt of a dialkyl chlorophosphate, with an alkyl chloroformate, with an aryl isocyanate or with a carboxylic acid chloride.
  • the compounds of formula I can be converted in a known manner into their salts with physiologically acceptable acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid.
  • Salt formation is preferably effected in a solvent, for example diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or 2-butanone.
  • trimethylchlorosilane in aqueous solution is suitable for the preparation of hydrochlorides.
  • 1-phenyl-3-dimethylaminopropane compounds of formula I are toxicologically harmless, so that they are suitable as pharmaceutical active ingredients in drugs.
  • the present invention also relates to the use of a 1-phenyl-3-dimethylaminopropane compound of formula I as a pharmaceutical active ingredient.
  • Compounds of formula I are preferably used for the treatment of pain.
  • the analgesics according to the invention may contain carriers, fillers, solvents, diluents, colorants and/or binders.
  • auxiliary substances and of the amounts of the same to be used depends on whether the drug is to be administered orally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally or locally, for example for infections of the skin, of the mucous membranes or of the eye. Preparations in the form of tablets, dragees, capsules, granules, drops, liquids and syrups are suitable for oral application.
  • Solutions, suspensions, readily reconstitutable dry preparations, and sprays are suitable for parenteral, topical and inhalative applications.
  • Compounds of formula I according to the invention in a deposit in dissolved form or in a patch, optionally with the addition of a skin penetration promoter, are suitable preparations for percutaneous application.
  • Forms of preparations which can be administered orally or percutaneously may effect delayed release of the compounds of formula I according to the invention.
  • the amount of active ingredient to be administered to patients varies depending on the patient's weight, on the manner of administration, the indication and the degree of severity of the illness. 50 to 500 mg/kg of at least one 1-phenyl-3-dimethylaminopropane compound of formula I are usually administered.
  • Racemate separation was effected on a Chiracel OD column.
  • RT denotes room temperature
  • m.p. denotes melting point
  • the Grignard solution was decomposed by the addition of 300 ml of 20% ammonium chloride solution.
  • the reaction mixture was diluted with 400 ml ether, the organic phase was separated off and the aqueous phase was extracted twice with 250 ml ether.
  • the combined organic phases were dried over sodium sulphate. After removing the solvent by distillation, the residue (212 g) was taken up in 3200 ml 2-butanone and added to 120.60 g (1.11 mole) trimethylchlorosilane and 20 ml water. 121.5 g of hydrochloride (1) (38% theoretical) with a melting point of 198-199° C. crystallised out at 4-5° C.
  • the base was released from (1) with dichloromethane/sodium hydroxide solution. After drying the solution dichloromethane was distilled off under vacuum. The racemate was then separated on the chiral HPLC column.
  • the hydrochlorides which had a melting point of 150-151° C., were prepared from the enantiomers obtained by reaction with trimethylchlorosilane/water in 2-butanone.
  • reaction mixture was allowed to stand for 12 hours at room temperature, and was then cooled again to 5-10° C. and added to 35 ml of 20% aqueous ammonium chloride solution. After phase separation, the aqueous phase was extracted twice with 50 ml ether. The combined organic phases were dried over sodium sulphate. After removing the solvent by distillation the residue (3.9 g) was introduced on to a 5 ⁇ 16 cm column packed with silica gel 0.95 g of base were obtained by elution with 7:1 diisopropyl ether/methanol, from which 0.82 g of hydrochloride (10) (15.5% theoretical) with a melting point of 162° C. were obtained with trimethylchlorosilane/water in ethyl acetate/2-butanone.
  • Example 2 44 g of crude mixture were obtained as in Example 1 from 20 g (140 mmole) 1-dimethylamino-2-methylpentan-3-one, 31.5 g (140 mmole) 1-bromo-4-trifluoromethylbenzene, 16.5 g (680 mmole) magnesium turnings and 47 ml 1,2-dibromomethane.
  • This mixture was introduced on to a 7 ⁇ 50 cm column packed with silica gel and eluted with 5:1 ethyl acetate/methanol. 16.4 g of base were obtained, from which 12.3 g of hydrochloride (11) (27% theoretical) with a melting point of 170-171° C. were obtained with trimethylchlorosilane/water in 2-butanone.
  • the base was released from hydrochloride (15), which was prepared as in Example 16, with dichloromethane/sodium hydroxide solution. After drying and removal of dichloromethane by distillation, the racemate was then separated into the enantiomers on a chiral HPLC column.
  • the hydrochlorides were obtained from the enantiomers with trimethylchlorosilane/water in 2-butanone.
  • the base was released from compound (1), which was prepared as in Example 1, with dichloromethane/sodium hydroxide solution. After drying the solution, dichloromethane was removed by distillation. 4.3 g (17 mmole) of base were dissolved in 25 ml dry toluene and slowly added drop-wise to 71 ml (85 mmole) of a 1.2 molar solution of diisobutylaluminium hydride in toluene. When the addition was complete, the mixture was heated for 8 hours under reflux and then cooled to room temperature. The reaction mixture was diluted with 25 ml toluene. 9.4 ml ethanol followed by 9.4 ml water were added drop-wise whilst cooling in an ice bath.
  • Enantiomer ( ⁇ 18) was obtained in a yield of 29% theoretical from enantiomer ( ⁇ 16) obtained as in Example 19, under the conditions cited in Example 22.
  • the base was released from enantiomer (+1), which was prepared as in Example 2, with dichloromethane/sodium hydroxide solution. After drying the solution, dichloromethane was removed by distillation. 3.0 g (39 mmole) acetyl chloride were added drop-wise, whilst cooling in an ice bath, to 10 g (35 mmole) of the base obtained, which had been taken up in 150 ml of dry dichloromethane. After the addition of acetyl chloride was complete, the reaction mixture was warmed to room temperature, and after stirring for two hours was mixed with 100 ml of saturated sodium hydrogen carbonate solution.
  • the organic phase was separated from the aqueous phase and the aqueous phase was extracted twice with 50 ml dichloromethane.
  • the organic phases were combined and dried over sodium sulphate. After removing the solvent by distillation, 13.4 g crude mixture were obtained, from which 10.7 g, of hydrochloride (+24) (93% theoretical) was obtained with trimethylchlorosilane/water in 2-butanone/ethyl acetate.
  • the base was released from (26) with dichloromethane/sodium hydroxide solution and after drying the solution dichloromethane was removed by distillation.
  • 8.3 g (30 mmole) of base were dissolved in 30 ml n-hexane and added drop-wise to a suspension consisting of 95 g pyridinium chlorochromate (prepared according to Synthesis 1980, 223) absorbed on neutral alumina.
  • the reaction mixture was mixed with 120 ml dichloromethane, stirred for a further 2 hours and then filtered through 30 g alumina.
  • the filter residue was washed three times by decantation with 50 ml dichloromethane and ether in each case.
  • the base was released from enantiomer (+21), which was prepared as in Example 24, with dichloromethane/sodium hydroxide solution, and after drying the solution dichloromethane was removed by distillation.
  • 2.2 g (10 mmole) of the base obtained were dissolved in 20 ml of dry toluene and mixed with 1.8 g (11 mmole) 4-isopropylphenyl isocyanate. After stirring for 20 hours at room temperature the toluene was removed by distillation. The residue was reacted with trimethylchlorosilane/water in n-propyl acetate to form 3.2 g of hydrochloride ( ⁇ 28) (76% theoretical).
  • mice Male NMRI mice with a weight between 25 and 30 g were used for this purpose.
  • each 10 animals received, 30 minutes after the oral administration of a compound according to the invention, 0.3 ml per mouse of an 0.02% aqueous phenylquinone solution (phenylbenzoquinone manufactured by Sigma, Deisenhofen; solution prepared with the addition of 5% ethanol and kept on a water bath at 45° C.) administered intraperitoneally.
  • aqueous phenylquinone solution phenylbenzoquinone manufactured by Sigma, Deisenhofen; solution prepared with the addition of 5% ethanol and kept on a water bath at 45° C.

Abstract

1-phenyl-3-dimethylaminopropane compounds corresponding to the formula I
Figure USRE039593-20070424-C00001
a method of preparing them, and the use of these substances as analgesic active ingredients in pharmaceutical compositions.

Description

CROSS REFERENCE TO RELATED APPLICATION
This application is a reissue of U.S. Pat. No. 6,248,737.
BACKGROUND OF THE INVENTION
The present invention relates to 1-phenyl-3-dimethylaminopropane compounds, to a method of preparing them, and to the use of these substances as pharmaceutical active ingredients.
The treatment of chronic and non-chronic pain situations is of great importance in medicine. This is reflected in the large number of publications. Thus, for example, 1-naphthyl-3-aminopropane-1-ols with an analgesic-narcotic effect are known from EP 176 049. Secondary and tertiary alcohols with γ-amino groups are described in J. Pharm. Sci. 59, 1038 (1970) and in J. Prakt. Chem. 323, 793 (1981); phenyl-dimethylaminopropanols containing a para-substituted phenyl radical are described in Chem. Abstr. 54, 20963c (1960) and in Chem. Abstr. 63, 6912e (1965). These compounds also possess analgesic properties. In contrast, the 3-dimethylaminopropan-1-ols containing 2-phenyl radicals described in DE 32 42 922 have an antidepressant effect. The 1-phenyl-propan-1-ols described in J. Pharm. Sci. 57, 1487 (1968) have different pharmacological effects depending on the γ-aza ring.
Opioids have been used for many years as analgesics for the treatment of pain, although they give rise to a series of side effects, for example addiction and dependency, respiratory depression, gastrointestinal inhibition and obstipation. They can therefore only be given over an extended period of time or in higher doses subject to special precautionary measures such as special prescription regulations (Goodman, Gilman in “The Pharmacological Basis of Therapeutics”, Pergamon Press, New York (1990)).
Tramadol hydrochloride—(1RS,2RS)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) cyclohexanol hydrochloride—assumes a special position amongst centrally-acting analgesics, since this active ingredient gives rise to a pronounced inhibition of pain without the side effects which are known for opioids (J. Pharmacol. Exptl. Ther.4 267, 331 (1993)). Tramadol is a racemate and consists of identical amounts of (+) and (−) enantiomer. In vivo the active ingredient forms the metabolite O-desmethyl-tramadol, which is likewise present as a mixture of enantiomers. Investigations have shown that both the enantiomers of tramadol and the enantiomers of tramadol metabolites contribute to the analgesic effect (J. Pharmacol. Exp. Ther. 260, 275 (1992)).
SUMMARY OF THE INVENTION
The underlying object of the present invention was to provide substances with an analgesic effect, which are suitable for the treatment of severe pain without giving rise to the side effects which are typical of opioids.
A further object was to provide analgesic substances which do not exhibit the side effects, for example nausea and vomiting, which occur during treatment with tramadol in some cases.
It has been found that these stringent requirements are fulfilled by certain 1-phenyl-3-dimethylaminopropane compounds. These substances are characterized by a pronounced analgesic effect which is significantly enhanced compared with that of tramadol.
The present invention accordingly relates to 1-phenyl-3-dimethylaminopropane compounds of formula I
Figure USRE039593-20070424-C00002
in which
  • X represents OH, F, Cl, H or an OCOR6 group in which R6 is a C1-3-alkyl group;
  • R1 is a C1-4-alkyl group;
  • R2 represents H or a C1-4-alkyl group and R3 represents H or a straight chain C1-4-alkyl group, or R2 and R3 together constitute a C4-7 cycloalkyl radical, and
  • if R5 is H, R4 represents meta-O-Z, where Z is H, C1-4-alkyl, PO(OC1-4-alkyl)2, CO(OC1-5-alkyl), CONH—C6H4—(C1-3-alkyl) or CO—C6H4—R7, wherein R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2, where R8 is C1-4-alkyl or 4-morpholino, or R4. represents meta-S-C1-3-alkyl, meta-Cl, meta-F or meta-CR9R10R11, ortho-OH, ortho-O-C2-3-alkyl, para-F or para-CR9R10R11, where R9, R10 and R11 represent H or F, or
  • if R5 represents Cl, F, OH or O—C1-3-alkyl in the para-position, R4 represents Cl, F, OH or O—C1-3-alkyl in the meta-position, or
  • R4 and R5 together represent 3,4-OCH═CH— or 3,4-OCH═CHO—, as diastereoisomers or enantiomers in the form of free bases or salts of physiologically acceptable acids.
1-phenyl-3-dimethylaminopropane compounds of formula I are preferred in which X constitutes OH, F, Cl or H; R1 represents a C1-4-alkyl group; R2 represents H or CH3, and R3 represents H or CH3, and if R5 is H, R4 represents OC1-3-alkyl, —OH, —S—C1-3-alkyl, F, Cl, CH3, —CF2H or —CF3 in the meta-position, or para-CF3, or if R5 is a para-Cl or para-F, R4 represents meta-Cl or meta-F, or R4 and R5 together represent 3,4-OCH═CH—.
1-phenyl-3-dimethylaminopropane compounds of formula I are particularly preferred in which the R2 and R3 radicals have different meanings, in the form of their diastereoisomers of configuration Ia
Figure USRE039593-20070424-C00003
The present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which the variable X represents OH, which is characterized in that a β-dimethylaminoketone of formula II
Figure USRE039593-20070424-C00004
is reacted with an organometallic compound of formula III
Figure USRE039593-20070424-C00005
in which Z represents MgCl, MgBr, MgI or Li, to form a compound of formula I in which X represents OH.
The reaction of a β-dimethylaminoketone with a Grignard reagent of formula III, in which Z represents MgCl, MgBr or MgI, or with an organolithium compound of formula III, can be carried out in an a liphatic ether, for example diethyl ether and/or tetrahydrofuran, at temperatures between −70° C. and +60° C. Organolithium compounds of formula II can be obtained by the replacement of halogen by lithium, for example, by reacting a compound of formula III, in which Z represents Cl, Br or I, with a solution of n-butyllithium in n-hexane. β-dimethylaminoketones of formula II can be obtained from ketones of general formula IV
Figure USRE039593-20070424-C00006
by reaction with dimethylamine hydrochloride and formaldehyde in glacial acetic acid or in a C1-4-alkyl alcohol or by reaction with dimethylammonium ethylene chloride in acetonitrile using acetyl chloride as a catalyst (Synthesis 1973, 703).
Upon reaction of a β-dimethylaminoketone of formula II, in which the variables R2 and R3 have different meanings, with an organometallic compound of formula III, 1-phenyl-3-dimethylaminopropane compounds of formula I are obtained having the relative configuration of formula Ia
Figure USRE039593-20070424-C00007
in which the X and the dimethylamino group are disposed threo in relation to each other. In contrast, if the reaction for the preparation of 1-phenyl-1-hydroxy-3-aminopropanes were carried out according to the method disclosed in DD 124 521, i.e. if β-aminoketones corresponding to the formula
Figure USRE039593-20070424-C00008
were reacted with an alkyl Grignard reagent R1MgHal, this would result in compounds with the relative configuration Ib
Figure USRE039593-20070424-C00009
in which the OH X group and the dimethylamino radical are disposed erythro in relation to each other.
1-phenyl-3-dimethylaminopropane compounds of formula I, in which R4 and/or R5 constitute the OH group, can be prepared from the corresponding 1-(4(5)-methoxyphenyl)-3-dimethylaminopropanol compounds by selective ether cleavage with diisobutylaluminium hydride in an aromatic hydrocarbon, for example toluene, at a temperature between 60 and 130° C. (Synthesis 1975, 617).
The present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents H, which is characterized in that a compound of formula I, in which X represents Cl, is reacted with zinc borohydride, zinc cyanoborohydride and/or tin cyanoborohydride.
The reaction is usually conducted in a solvent, for example diethyl ether and/or tetrahydrofuran, at a temperature between 0° C. and 30° C.
Compounds of formula I, in which X is H and R4 and/or R5 constitute the OH group, can be prepared from the corresponding methoxyphenyl compounds by heating them for several hours with concentrated hydrobromic acid (Chem. Rev. 54, 615 (1954); J. Am. Chem. Soc. 74, 1316 (1952)).
The present invention further relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, where X represents F, which is characterized in that a compound of formula I, in which X represents OH, is reacted with dimethylaminosulfur trifluoride in a solvent.
Suitable solvents include dichloromethane, 1,1,2-trichloroethane and/or toluene. The reaction is usually conducted at a temperature between −50° C. and +30° C. (Org. React. 35, 513 (1988)). If a compound of formula I with X═OH is used in which R4 and/or R5 constitute OH groups, these OH groups must be protected before reaction with the fluorine compound, for example by reaction with benzoyl chloride.
The present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents Cl, which is characterized in that a compound of formula I, in which X represents OH, is reacted with thionyl chloride.
The reaction is usually conducted in the absence of solvent at a temperature between 0° C. and 20° C. Replacement of OH by Cl is effected while maintaining the configuration.
The present invention also relates to a method of preparing 1-phenyl-3-dimethylaminopropane compounds of formula I, in which X represents an OCOR6 group where R6 is a C1-3-alkyl, which is characterized in that a compound of formula I, in which X represents OH, is reacted with an acid chloride Cl—COOR6.
The reaction is preferably conducted in a solvent, for example dichloromethane, toluene and/or tetrahydrofuran, at a temperature between −10° C. and +30° C.
1-phenyl-3-dimethylaminopropane compounds of formula I, in which R5 is H and R4 is a meta-phosphate group, meta-carbonate group, meta-carbamate group or meta-carboxylate group, can be obtained by the reaction of the corresponding 1-(3-hydroxyphenyl)-3-dimethylaminopropane compounds of formula I in the form of their alkali salts with an alkali salt of a dialkyl chlorophosphate, with an alkyl chloroformate, with an aryl isocyanate or with a carboxylic acid chloride. These reactions are usually conducted in a solvent, for example toluene, dichloromethane, diethyl ether and/or tetrahydrofuran, at temperatures between −15° C. and +110° C. (Drugs of the Future 16, 443 (1991); J. Med. Chem. 30, 2008 (1987) and 32, 2503 (1989); J. Org. Chem. 43, 4797 (1978); Tetrahedron Lett. 1977, 1571; J. Pharm. Sci. 57, 774 (1968)).
The compounds of formula I can be converted in a known manner into their salts with physiologically acceptable acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, formic acid, acetic acid, oxalic acid, succinic acid, tartaric acid, mandelic acid, fumaric acid, lactic acid, citric acid, glutamic acid and/or aspartic acid. Salt formation is preferably effected in a solvent, for example diethyl ether, diisopropyl ether, alkyl acetates, acetone and/or 2-butanone. Moreover, trimethylchlorosilane in aqueous solution is suitable for the preparation of hydrochlorides.
1-phenyl-3-dimethylaminopropane compounds of formula I are toxicologically harmless, so that they are suitable as pharmaceutical active ingredients in drugs.
Accordingly, the present invention also relates to the use of a 1-phenyl-3-dimethylaminopropane compound of formula I as a pharmaceutical active ingredient. Compounds of formula I are preferably used for the treatment of pain.
In addition to at least one 1-phenyl-3-dimethylaminopropane compound of formula I, the analgesics according to the invention may contain carriers, fillers, solvents, diluents, colorants and/or binders. The selection of auxiliary substances and of the amounts of the same to be used depends on whether the drug is to be administered orally, intravenously, intraperitoneally, intradermally, intramuscularly, intranasally or locally, for example for infections of the skin, of the mucous membranes or of the eye. Preparations in the form of tablets, dragees, capsules, granules, drops, liquids and syrups are suitable for oral application. Solutions, suspensions, readily reconstitutable dry preparations, and sprays are suitable for parenteral, topical and inhalative applications. Compounds of formula I according to the invention in a deposit in dissolved form or in a patch, optionally with the addition of a skin penetration promoter, are suitable preparations for percutaneous application. Forms of preparations which can be administered orally or percutaneously may effect delayed release of the compounds of formula I according to the invention.
The amount of active ingredient to be administered to patients varies depending on the patient's weight, on the manner of administration, the indication and the degree of severity of the illness. 50 to 500 mg/kg of at least one 1-phenyl-3-dimethylaminopropane compound of formula I are usually administered.
EXAMPLES
The yields of the compounds prepared have not been optimised.
All temperatures are uncorrected.
Unless otherwise indicated, petroleum ether with a boiling point of 50-70° C. was used. The term “ether” denotes diethyl ether.
Silica gel 60 (0.040-0.063 mm) manufactured by E. Merck, Darmstadt, was used as the stationary phase for column chromatography.
This layer chromatography investigations were conducted using prefabricated silica gel 60 F 254 HPTLC plates manufactured by E. Merck, Darmstadt.
Racemate separation was effected on a Chiracel OD column.
The mixture ratios of the mobile phases for all chromatographic investigations are expressed as volume/volume.
RT denotes room temperature; m.p. denotes melting point.
Example 1
Figure USRE039593-20070424-C00010
(2RS,3RS)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol Hydrochloride(1)
207.63 g (1.11 mole) 3-bromoanisole dissolved in 400 ml dry tetrahydrofuran were added drop-wise to 26.99 g (1.11 mole) magnesium turnings in 150 ml dry tetrahydrofuran so that the reaction mixture boiled gently. After the addition of 3-bromoanisole was complete the mixture was heated under reflux for one hour and thereafter was cooled to 5-10° C. 128.30 g (0.89 mole) 1-dimethylamino-2-methylpentan-3-one dissolved in 400 ml tetrahydrofuran were added at this temperature. The reaction mixture was allowed to stand overnight and then cooled again to 5-10° C. The Grignard solution was decomposed by the addition of 300 ml of 20% ammonium chloride solution. The reaction mixture was diluted with 400 ml ether, the organic phase was separated off and the aqueous phase was extracted twice with 250 ml ether. The combined organic phases were dried over sodium sulphate. After removing the solvent by distillation, the residue (212 g) was taken up in 3200 ml 2-butanone and added to 120.60 g (1.11 mole) trimethylchlorosilane and 20 ml water. 121.5 g of hydrochloride (1) (38% theoretical) with a melting point of 198-199° C. crystallised out at 4-5° C.
Example 2
Figure USRE039593-20070424-C00011
Enantiomers of (1):
  • (−)-(2S,3S)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol Hydrochloride(−1)
    and
  • (+)-(2R,3R)-1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol Hydrochloride(+1).
The base was released from (1) with dichloromethane/sodium hydroxide solution. After drying the solution dichloromethane was distilled off under vacuum. The racemate was then separated on the chiral HPLC column. The hydrochlorides, which had a melting point of 150-151° C., were prepared from the enantiomers obtained by reaction with trimethylchlorosilane/water in 2-butanone.
(−1):
yield: 42% theoretical
[α]D RT =−31.8° (c=0.99; methanol)
(+1):
yield: 41% theoretical
[α]D =RT +33.0° (c=0.96; methanol)
Example 3
Figure USRE039593-20070424-C00012
(2RS,3RS)-3-(3,4-dichlorophenyl)-1-dimethylamino-2-methylpentan-3-ol Hydrochloride (2)
39 g of crude mixture were prepared analogously to Example 1 from 15 g (105 mmol) 1-dimethylamino-2-methylpentan-3-one, 35.5 g (157 mmole) 4-bromo-1,2-dichlorobenzene and 3.8 g (157 mmole) magnesium turnings. This mixture was introduced on to a 7×40 cm column packed with silica gel and eluted with 4:1 ethyl acetate/methanol. 14.9 g of base were obtained, from which 11.2 g of hydrochloride (2) (31% theoretical) with a melting point of 183-184° C. were obtained with trimethylchlorosilane/water in 2-butanone/diisopropyl ether.
Example 4
Figure USRE039593-20070424-C00013
(2RS,3RS)-3-(3-isopropoxyphenyl)-1-dimethylamino-2-methylpentan-3-ol Hydrochloride (3)
25 g of crude mixture were prepared analogously to Example 1 from 14.3 g (100 mmol) 1-dimethylamino-2-methylpentan-3-one, 20.0 g (157 mmole) 1-bromo-3-isopropoxybenzene and 2.79 g (115 mmole) magnesium turnings. This mixture was introduced on to a 7×40 cm column packed with silica gel and eluted with 15:1 ethyl acetate/methanol. 9.0 g of base were obtained, from which 8.3 g of hydrochloride (3) (26% theoretical) with a melting point of 133-134° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 5
Figure USRE039593-20070424-C00014
(2RS,3RS)-3-(3-chlorophenyl)-1-dimethylamino-2-methylpentan-3-ol Hydrochloride (4)
63 g of crude mixture were obtained under the conditions cited for Example 1 from 38.0 g (270 mmole) 1-dimethylamino-2-methylpentan-3-one, 74.7 g (390 mmol) 1 -bromo-3-chlorobenzene and 9.50 g (390 mmole) magnesium turnings. This mixture was introduced on to a 7×45 cm column packed with silica gel and eluted with 7:1 diisopropyl ether/methanol. 12.8 g of base were obtained, from which 10.8 g of hydrochloride (4) (14% theoretical) with a melting point of 160-162° C. were obtained with trimethylchlorosilane/water in 2-butanone/ether.
Example 6
Figure USRE039593-20070424-C00015
(2RS,3RS)-1-dimethylamino-2-methyl-3-(3-trifluoromethylphenyl)-pentan-3-ol Hydrochloride(5)
21.2 g of crude mixture were obtained under the conditions cited for Example 1 from 14.3 g (100 mmole) 1-dimethylamino-2-methylpentan-3-one, 29.3 g (130 mmole) 1-bromo-3-trifluoromethylbenzene and 3.2 g (130 mmole) magnesium turnings. This mixture was introduced on to a 6×40 cm column packed with silica gel and eluted with 10:1 diisopropyl ether/methanol. 9.1 g of base were obtained, from which 7.8 g of hydrochloride (5) (18.5% theoretical) with a melting point of 189-190° C. was obtained with trimethylchlorosilane/water in 2-butanone.
Example 7
Figure USRE039593-20070424-C00016
(2RS,3RS)-1-dimethylamino-2-methyl-3-(3-m-tolyl)-pentan-3-ol Hydrochloride (6)
75 g of crude mixture were obtained as in Example 1 from 47.3 g (330 mmole) 1-dimethylamino-2-methylpentan-3-one, 64.6 g (400 mmole) 3-bromotoluene and 9.72 g (400 mmole) of magnesium turnings. This mixture was introduced on to a 7×50 cm column packed with silica gel and eluted with 7:1 diisopropyl ether/methanol. 24.3 g of base were obtained, from which 21.5 g of hydrochloride (6) (24% theoretical) with a melting point of 154-155° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 8
Figure USRE039593-20070424-C00017
(2RS, 3RS)-1-dimethylamino-3-(3-fluorophenyl)-2-methylpentan-3-ol Hydrochloride (7)
70 g of crude mixture were obtained under the conditions cited for Example 1 from 54.0 g (380 mmole) 1-dimethylamino-2-methylpentan-3-one, 82.5 g (470 mmole) 1-bromo-3-fluorobenzene and 9.23 g (470 mmole) magnesium turnings. This mixture was introduced on to a 7×50 cm column packed with silica gel and eluted with 1:1 ethyl acetate/methanol. 13.0 g of base were obtained, from which 11.2 g of hydrochloride (7) (11.5% theoretical) with a melting point of 145-146° C. was obtained with trimethylchlorosilane/water in 2-butanone.
Example 9
Figure USRE039593-20070424-C00018
(2RS,3RS)-3-(3-difluoromethylphenyl)-1-dimethylamino-2-methylpentan-3-ol Hydrochloride(8)
7.0 g (34 mmole) 1-bromo-3-difluoromethylbenzene, prepared from 3-bromobenzaldehyde and diethylaminosulphur trifluoride in dichloromethane according to Org. React. 35, 513 (1988) were dissolved in 110 ml of dry tetrahydrofuran and cooled to −75° C. After the addition of 21.12 ml (34 mmole) of a 1.6 molar solution of n-butyllithium in hexane the mixture was stirred for one hour at −75° C. 4.8 g (34 mmole) 1-dimethylamino-2-methylpentan-3-one dissolved in 15 ml of dry tetrahydrofuran were then added dropwise. The reaction mixture was warmed to room temperature over 2.5 hours.
Work-up was effected by the drop-wise addition of 65 ml of 5% hydrochloric acid with cooling in an ice bath, so that the internal temperature did not exceed 15° C. After phase separation the organic phase was extracted with 40 ml of 5% hydrochloric acid. The combined aqueous phases were washed twice with 50 ml ether. In order to release the base, the mixture was added to concentrated sodium hydroxide solution and extracted with dichloromethane. 7.8 g of crude product were obtained in this manner and was introduced on to a 7×40 cm column packed with silica gel. Elution with 1:1 ethyl acetate/methanol gave 4.89 g of base, from which 4.6 g of hydrochloride (8) (44% theoretical) with a melting point of 194-195° C. was obtained with trimethylchlorosilane/water in 2-butanone.
Example 10
Figure USRE039593-20070424-C00019
(2RS,3RS)-1-dimethylamino-2-methyl-3-(3-methylsulphanylphenyl)-pentan-3-ol Hydrochloride(9)
38 g of crude mixture were obtained under the conditions cited for Example 1 from 17.6 g (123 mmole) 1-dimethylamino-2-methylpentan-3-one, 25.0 g (123 mmole) 1-bromo-3-methylsulphanylbenzene and 3.0 g (123 mmole) magnesium turnings. This mixture was introduced on to a 7×40 cm column packed with silica gel and eluted with 10:1 ethyl acetate/methanol. 8.35 g of base were obtained, from which 7.2 g of hydrochloride (9) (19% theoretical) with a melting point of 159-160° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 11
Figure USRE039593-20070424-C00020
(2RS,3RS)-3-benzofuran-6-yl-1-dimethylamino-2-methylpentan-3-ol Hydrochloride(10)
3.45 g (18 mmole) 6-bromobenzofurane (prepared according to EP 355 827) and 6 ml 1,2-dibromoethane, dissolved in 60 ml dry ether, were added drop-wise over 1.5 hours to 2.12 g (87 mmole) magnesium turnings in 30 ml dry ether; after the addition the mixture was heated under reflux for 30 minutes. Thereafter, 2.5 g (18 mmole) 1-dimethylamino-2-methylpentan-3-one dissolved in 7.5 ml ether was added drop-wise over 1.5 hours whilst cooling in an ice bath to maintain an internal temperature of 5-10° C. The reaction mixture was allowed to stand for 12 hours at room temperature, and was then cooled again to 5-10° C. and added to 35 ml of 20% aqueous ammonium chloride solution. After phase separation, the aqueous phase was extracted twice with 50 ml ether. The combined organic phases were dried over sodium sulphate. After removing the solvent by distillation the residue (3.9 g) was introduced on to a 5×16 cm column packed with silica gel 0.95 g of base were obtained by elution with 7:1 diisopropyl ether/methanol, from which 0.82 g of hydrochloride (10) (15.5% theoretical) with a melting point of 162° C. were obtained with trimethylchlorosilane/water in ethyl acetate/2-butanone.
Example 12
Figure USRE039593-20070424-C00021
(2RS,3RS)-1-dimethylamino-2-methyl-3-(4-trifluoromethylphenyl)-pentan-3-ol Hydrochloride (11)
44 g of crude mixture were obtained as in Example 1 from 20 g (140 mmole) 1-dimethylamino-2-methylpentan-3-one, 31.5 g (140 mmole) 1-bromo-4-trifluoromethylbenzene, 16.5 g (680 mmole) magnesium turnings and 47 ml 1,2-dibromomethane. This mixture was introduced on to a 7×50 cm column packed with silica gel and eluted with 5:1 ethyl acetate/methanol. 16.4 g of base were obtained, from which 12.3 g of hydrochloride (11) (27% theoretical) with a melting point of 170-171° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 13
(3RS)-1-dimethylamino-3-(3-methoxyphenyl)-hexan-3-ol Hydrochloride (12)
18.5 g of crude mixture were obtained as in Example 1 from 10 g (70 mmole) 1-dimethylamino-hexan-3-one, 18.7 g (100 mmole) 1-bromo-3-methoxybenzene and 2.3 g (100 mmole) magnesium turnings. This mixture was introduced on to a 6×50 cm column packed with silica gel and eluted with 1:1 ethyl acetate/methanol. 6.84 g of base were obtained, from which 6.15 g of hydrochloride (12) (32% theoretical) with a melting point of 179-180° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 14
(3RS)-1-dimethylamino-3-(3-methoxyphenyl)-heptan-3-ol Hydrochloride (13)
17.3 g of crude mixture were obtained as in Example 1 from 10 g (64 mmole) 1-dimethylamino-heptan-3-one, 15.9 g (157 mmole) 1-bromo-3-methoxybenzene and 2.06 g (85 mmole) magnesium turnings. This mixture was introduced on to a 6×40 cm column packed with silica gel and eluted with ethyl acetate. 5.4 g of base were obtained, from which 4.1 g of hydrochloride (13) (21% theoretical) with a melting point of 150° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 15
(3RS)-1-dimethylamino-3-(3-methoxyphenyl)-4,4-dimethylpentan-3-ol Hydrochloride(14)
37 g of crude mixture were obtained as in Example 1 from 18.6 g (118 mmole) 1-dimethylamino-4,4-dimethylpentan-3-one, 28.4 g (152 mmole) 1-bromo-3-methoxybenzene and 3.7 g (152 mmole) magnesium turnings. This mixture was introduced on to a 7×40 cm column packed with silica gel and eluted with 5:1 ethyl acetate/methanol. 2.2 g of base were obtained, from which 1.8 g of hydrochloride (14) (5% theoretical) with a melting point of 213° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 16
Figure USRE039593-20070424-C00022
(2RS,3RS)-4-dimethylamino-2-(3-methoxyphenyl)-3-methylbutan-3-ol Hydrochloride(15)
21 g of crude mixture were obtained as in Example 1 from 5.3 g (41 mmole) 4-dimethylamino-3-methylbutan-3-one, 23.0 g (123 mmole) 1-bromo-3-methoxybenzene and 3.0 g (123 mmole) magnesium turnings. This mixture was introduced on to a 4.5×27 cm column packed with silica gel and eluted with 4:1 ethyl acetate/methanol. 4.0 g of base were obtained, from which 3.6 g of hydrochloride (15) (32%) theoretical) with a melting point of 124° C. were obtained with trimethylchlorosilane/water in 2-butanone.
Example 17
Figure USRE039593-20070424-C00023
Enantiomers of (15):
  • (−)-(2S,3S)-4-dimethylamino-2-(3-methoxyphenyl)-3-methylbutan-3-ol Hydrochloride (−15)
    and
  • (+)-(2R,3R)-4-dimethylamino-2-(3-methoxyphenyl)-3-methylbutan-3-ol Hydrochloride(+15).
The base was released from hydrochloride (15), which was prepared as in Example 16, with dichloromethane/sodium hydroxide solution. After drying and removal of dichloromethane by distillation, the racemate was then separated into the enantiomers on a chiral HPLC column. The hydrochlorides were obtained from the enantiomers with trimethylchlorosilane/water in 2-butanone.
(−15):
yield: 41% theoretical
m.p.: 117-118° C.
[α]D RT =−38.6° (c=1.05; methanol)
(+15):
yield: 41% theoretical
m.p.: 118-119° C.
[α]D RT =+41.0° (c=1.01; methanol)
Example 18
Figure USRE039593-20070424-C00024
(2RS,3RS)-3-(3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol Hydrochloride(16).
The base was released from compound (1), which was prepared as in Example 1, with dichloromethane/sodium hydroxide solution. After drying the solution, dichloromethane was removed by distillation. 4.3 g (17 mmole) of base were dissolved in 25 ml dry toluene and slowly added drop-wise to 71 ml (85 mmole) of a 1.2 molar solution of diisobutylaluminium hydride in toluene. When the addition was complete, the mixture was heated for 8 hours under reflux and then cooled to room temperature. The reaction mixture was diluted with 25 ml toluene. 9.4 ml ethanol followed by 9.4 ml water were added drop-wise whilst cooling in an ice bath. After stirring for one hour whilst cooling in the ice bath the reaction mixture was freed from aluminium salts by filtration, and the residue was washed three times with 50 ml toluene in each case. Thereafter the combined organic phases were dried and toluene was removed by distillation. 3.95 g of hydrochloride (16) (85% theoretical) with a melting point of 213-214° C. were obtained from the base with aqueous hydrochloric acid solution in acetone.
Example 19
Figure USRE039593-20070424-C00025
Enantiomers of (16):
(-) (2S,3S) 1S,2S)-3-(dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol Hydrochloride (-16) and
(+) (2S,3S 1R,2R)-3-(dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol Hydrochloride (+16)
The enantiomers (−16) and (+16) were prepared under the conditions cited in Example 2.
(−16):
yield: 85% theoretical
m.p.: 208-209° C.
[α]D RT =−34.6° (c=0.98; methanol)
(+16):
yield: 85% theoretical
m.p.: 206-207° C.
[α]D RT =+34.4° (c=1.06; methanol)
Example 20
Figure USRE039593-20070424-C00026
(1RS,2RS)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropylphenol Hydrochloride(17)
Compound (17) was prepared under the conditions cited in Example 18 starting from methoxy compound (15) which was obtained as in Example 16.
Yield: 85% theoretical
m.p.: 232° C.
Example 21
Figure USRE039593-20070424-C00027
Enantiomers of (17):
  • (−)-(1S,2S)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)-phenol Hydrochloride(−17)
    and
    (+)-(1R,2R)-3-(3-dimethylamino-1-hydroxy-1,2-dimethylpropyl)-phenolhydrochloride(+17)
The enantiomers (−17) and (+17) were prepared under the conditions cited in Example 2.
(−17):
yield: 82% theoretical
m.p.: 204-205° C.
[α]D RT =−42.0° (c=0.94; methanol)
(+17):
yield: 83% theoretical
m.p.: 204-205° C.
[α]D RT =+41.2° (c=1.01; methanol)
Example 22
Figure USRE039593-20070424-C00028
(+)-(1R,2R)-3-(3-dimethylamino-1-ethyl-1-fluoro-2-methylpropyl)-phenol Hydrochloride(+18)
1st Step
Figure USRE039593-20070424-C00029
(+)-(1R,2R)-3-(3-benzyloxyphenyl)-1-dimethylamino-2-methylpentan-3-ol (+19)
The base was released with dichloromethane/sodium hydroxide solution from enantiomer (+16) obtained as in Example 19, and dichloromethane was removed by distillation after drying the solution. 5.3 g (22 mmole) of base were dissolved in 27 ml of dry dimethylformamide and added in several portions to 1.2 g of 50% sodium hydride. After the addition of 2.8 ml (24 mmole) benzoyl chloride the mixture was heated for three hours at 70° C. The reaction mixture was then cooled to room temperature and poured on to an ice/water mixture. It was extracted three times with 70 ml ether in each case. After drying the combined organic phases over sodium sulphate, the solvent was distilled off and the residue was introduced on to a 4.5×30 cm column packed with silica gel. 6.8 g of base (+19) (92% theoretical) were obtained as a light yellow, highly viscous oil by elution with diisopropyl ether/methanol.
2nd Step
Figure USRE039593-20070424-C00030
(+)-(2R,3R)-[3-(3-benzyloxyphenyl)-3-fluoro-2-methylpentyl]-dimethylamine(+20)
6.8 g (21 mmole) of (+19), dissolved in 80 ml dichloromethane, were added dropwise at −20° C. to a solution of 3.7 g (23 mmole) diethylaminosulphur trifluoride in 30 ml of dry dichloromethane. After the addition was complete, the mixture was stirred for 30 minutes at this temperature and then warmed to room temperature. After stirring for a further one hour at room temperature, the mixture was cooled to 0-5° C. and hydrolysed with 50 ml water. After phase separation, the aqueous phase was extracted twice with 50 ml dichloromethane. The combined organic phases were dried and freed from solvent by distillation under vacuum. The crude mixture obtained (8.04 g) was introduced on to a 6×50 cm column packed with silica gel and eluted with 1:1 ethyl acetate/methanol. 3.04 g of base (+20) (40% theoretical) were obtained as a light yellow, viscous oil.
3rd Step:
(+)-(1R,2R)-3-(3-dimethylamino-1-ethyl-1-fluoro-2-methylpropyl)-phenol Hydrochloride(+18)
3.0 g (91 mmole) of (+20) were dissolved in 15 ml of dry methanol and added to 0.44 g palladium on activated carbon (10% Pd) in a hydrogenation apparatus. 215 ml hydrogen was consumed after stirring for three hours at room temperature. The catalyst was removed by filtration, and the methanol was removed by distillation. 2.22 g of base were obtained, from which 2.0 g of hydrochloride (+18) (79% theoretical) were obtained with trimethylchlorosilane/water in 2-butanone.
m.p.: 174-176° C.
[α]D RT =+29.5° (c=1.08; methanol)
Example 23
Figure USRE039593-20070424-C00031
(−)-(1S,2S)-3-(3-dimethylamino-1-ethyl-1-fluoro-2-methylpropyl)-phenol Hydrochloride(−18)
Enantiomer (−18) was obtained in a yield of 29% theoretical from enantiomer (−16) obtained as in Example 19, under the conditions cited in Example 22.
m.p.: 170-172° C.
[α]D RT =−28.4° (c=1.03; methanol)
Example 24
Figure USRE039593-20070424-C00032
(+)-(1S,2R 2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride (+21)
1st Step:
Figure USRE039593-20070424-C00033
(+)-(2R,3R)-[3-chloro-3-(-3-methoxyphenyl)-2-methylpentyl]-dimethylamine Hydrochloride(+22)
10 g (35 mmole) of (+1), prepared as in Example 2, were added to 10 ml thionyl chloride at room temperature. Nitrogen was subsequently passed over the reaction mixture for two hours to remove excess thionyl chloride. After a fresh addition of 10 ml thionyl chloride the reaction mixture was allowed to stand for 12 hours before excess thionyl chloride was again removed over a period of 2.5 hours by means of a stream of nitrogen. After drying, the residue was dissolved in 10 ml of ice-cold 2-butanone and mixed with stirring with 200 ml ether and then with 140 ml diisopropyl ether. The supernatant solvent phase was decanted off and the remaining oil was again taken up in 10 ml 2-butanone. After the addition of seed crystals, 300 ml diisopropyl ether were added drop-wise with vigorous stirring over three hours, whereupon the hydrochloride crystallised out. 9.8 g of (22) (91% theoretical) were obtained.
m.p.: 120° C. (decomposition)
[α]D RT =+24.7° (c=1.01; methanol)
2nd Step:
Figure USRE039593-20070424-C00034
(+)-(2R 2S, 3S)-[3-(3-methoxyphenyl)-2-methylpentyl]-dimethylamine Hydrocholoride (+23)
46 g of dried zinc chloride were dissolved in 580 ml of dry ether and subsequently added drop-wise to a slurry of 31 g sodium borohydride in 1800 ml ether. After stirring for 12 hours, 500 ml were removed by decantation from the zinc borohydride suspension obtained and added drop-wise to 9.8 g (32 mmole) of (+22) in 200 ml of dry ether. The reaction mixture was stirred for 72 hours at room temperature and then added drop-wise to 40 ml of a saturated ammonium chloride solution with cooling in an ice bath. After phase separation, the ether phase was washed twice with saturated brine; after drying over sodium sulphate the solvent was distilled off under vacuum. 7.3 g of an amine-borane complex were obtained, which were dissolved in 100 ml of dry methanol to isolate the free base. After the addition of 7.5 g triphenylphosphine the mixture was heated for 18 hours under reflux. After removing the solvent by distillation the residue was added to 100 ml of 5% hydrochloric acid, and the hydrochloric acid phase was subsequently washed twice with 50 ml ether. Thereafter the hydrochloric acid phase was made alkaline with concentrated sodium hydroxide solution whilst cooling in an ice bath, and was solvent-extracted twice with 50 ml dichloromethane. After drying the combined organic phases over sodium sulphate the solvent was distilled off under vacuum and the remaining residue (5.2 g) was taken up in 2-butanone. After the addition of trimethylchlorosilane/water, 4.3 g of hydrochloride (+23) (50% theoretical) crystallised out.
m.p.: 163-164° C.
[α]D RT =+25.20 (c=0.95; methanol)
3rd Step:
(+)-(1S,2R 2S)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol Hydrochloride(+21)
4.3 g (15 mmole) of (+23) from step 2 were added to 100 ml of concentrated hydrobromic acid. The mixture was then heated under reflux for two hours. After cooling to room temperature the reaction mixture was concentrated under the vacuum from a water pump. The residue was treated with concentrated sodium hydrogen carbonate solution until an alkaline reaction was obtained. After extracting twice with 50 ml dichloromethane in each case the combined organic phases were dried over sodium sulphate. Dichloromethane was then distilled off under vacuum and the residue (4 g) was taken up in 2-butanone. After the addition of trimethylchlorosilane/water, 3.8 g of hydrochloride (+21) (98% theoretical) crystallised out.
m.p.: 194-196° C.
[α]D RT =+24.5° (c=1.10; methanol)
Example 25
Figure USRE039593-20070424-C00035
(-)-(1R,2S 2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride(-21)
Enantiomer (−21) was obtained in 45% yield under the conditions cited in Example 24 from (−1), which was prepared as in Example 2.
m.p.: 168-170° C.
[α]D RT =−27.5° (c=0.97; methanol)
Example 26
Figure USRE039593-20070424-C00036
(+)-(1R,2R)-acetic acid-3-dimethylamino-1-ethyl-1-(3-methyoxyphenyl)-2-methylpropyl Ester Hydrochloride(+24)
The base was released from enantiomer (+1), which was prepared as in Example 2, with dichloromethane/sodium hydroxide solution. After drying the solution, dichloromethane was removed by distillation. 3.0 g (39 mmole) acetyl chloride were added drop-wise, whilst cooling in an ice bath, to 10 g (35 mmole) of the base obtained, which had been taken up in 150 ml of dry dichloromethane. After the addition of acetyl chloride was complete, the reaction mixture was warmed to room temperature, and after stirring for two hours was mixed with 100 ml of saturated sodium hydrogen carbonate solution. The organic phase was separated from the aqueous phase and the aqueous phase was extracted twice with 50 ml dichloromethane. The organic phases were combined and dried over sodium sulphate. After removing the solvent by distillation, 13.4 g crude mixture were obtained, from which 10.7 g, of hydrochloride (+24) (93% theoretical) was obtained with trimethylchlorosilane/water in 2-butanone/ethyl acetate.
m.p.: 153° C.
[α]D RT =−17.3° (c=1.04; methanol)
Example 27
Figure USRE039593-20070424-C00037
(1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxyphenyl)-propan-1-ol Hydrochloride(25)
1st Step:
Figure USRE039593-20070424-C00038
(1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-(3-methoxyphenyl)-methanol Hydrochloride(26)
44 g crude mixture was obtained from 25 g (150 mmole) 1-dimethylaminomethyl-cyclohexane carbaldehyde, 32.9 g (180 mmole) 1-bromo-3-methoxybenzene and 4.3 g (180 mmole) magnesium turnings, under the conditions cited in Example 1. This mixture was introduced on to a 7×40 cm column packed with silica gel and eluted with 4:1 diisopropyl ether/methanol. 38 g of base were obtained, from which 40 g of hydrochloride (26) (85% theoretical) with a melting point of 235° C. were obtained with trimethylchlorosilane/water in 2-butanone.
2nd Step:
Figure USRE039593-20070424-C00039
(1RS)-(1-dimethylaminomethyl-cyclohexyl)-(3-methoxyphenyl)-methanone Hydrochloride(27)
The base was released from (26) with dichloromethane/sodium hydroxide solution and after drying the solution dichloromethane was removed by distillation. 8.3 g (30 mmole) of base were dissolved in 30 ml n-hexane and added drop-wise to a suspension consisting of 95 g pyridinium chlorochromate (prepared according to Synthesis 1980, 223) absorbed on neutral alumina. After stirring for 72 hours at room temperature the reaction mixture was mixed with 120 ml dichloromethane, stirred for a further 2 hours and then filtered through 30 g alumina. The filter residue was washed three times by decantation with 50 ml dichloromethane and ether in each case. The organic phases were combined with the filtrate and freed from solvent by distillation. The residue obtained was taken up in 60 ml of 2 Normal sodium hydroxide solution and extracted four times with 20 mg ethyl acetate in each case. After drying the combined organic phases, the solvent was removed by distillation. 4.8 g crude mixture were obtained, which was introduced on to a 6×30 cm column packed with silica gel and eluted, firstly with ethyl acetate, then with 9:1 ethyl acetate/methanol and finally with 4:1 ethyl acetate/methanol. 3.8 g of base were obtained, from which 3.1 g of hydrochloride (27) (33% theoretical) with a melting point of 174° C. were obtained with trichlorosilane/water in 2-butanone.
3rd Step:
(1RS)-1-(1-dimethylaminomethyl-cyclohexyl)-1-(3-methoxyphenyl)-propan-1-ol Hydrochloride(25)
3.0 g crude mixture was obtained, under the conditions cited in Example 1, from 2.8 g (10 mmole) of (27) in the form of the base, 1.4 g (13 mmole) bromoethane and 0.32 g (13 mmole) magnesium turnings, using ether as the solvent. This mixture was introduced on to a 3×20 cm column packed with silica gel and eluted with 19:1 diisopropyl ether/methanol, 2.1 g of base were obtained, from which 1.9 g of hydrochloride (25) (55% theoretical) with a melting point of 230° C. were obtained with trichlorosilane/water in 2-butanone/ethyl acetate.
Example 28
Figure USRE039593-20070424-C00040
(−)-(2R,3S)-{3[3-(p-isopropyl-phenyl-carbamoyl)-oxy-phenyl]-2-methylpentyl-dimethylamine Hydrochloride(−28)
The base was released from enantiomer (+21), which was prepared as in Example 24, with dichloromethane/sodium hydroxide solution, and after drying the solution dichloromethane was removed by distillation. 2.2 g (10 mmole) of the base obtained were dissolved in 20 ml of dry toluene and mixed with 1.8 g (11 mmole) 4-isopropylphenyl isocyanate. After stirring for 20 hours at room temperature the toluene was removed by distillation. The residue was reacted with trimethylchlorosilane/water in n-propyl acetate to form 3.2 g of hydrochloride (−28) (76% theoretical).
m.p.: 151-152° C.
[α]D RT =−5.2° (c=1.11; methanol)
Pharmacological Investigations
Writhing Test on Mice
The analgesic effectiveness of the compounds according to the invention was investigated in the phenylquinone-induced writhing test, modified according to I. C. Hendershot, J. Forsaith in J. Pharmacol. Exptl. Ther. 125, 237 (1959), on mice. Male NMRI mice with a weight between 25 and 30 g were used for this purpose. For each dose of substance, each 10 animals received, 30 minutes after the oral administration of a compound according to the invention, 0.3 ml per mouse of an 0.02% aqueous phenylquinone solution (phenylbenzoquinone manufactured by Sigma, Deisenhofen; solution prepared with the addition of 5% ethanol and kept on a water bath at 45° C.) administered intraperitoneally. Thereafter the animals were placed individually in observation cages. The number of pain-induced stretching movements (writhing reaction-straightening of the body with stretching of the rear extremities) was counted with the aid of a push-button counter. The Ed50 value (effective dose with 50% inhibition of writhing reaction) was calculated with a 95% confidence limit by means of regression analysis (evaluation program supplied by Martens EDV-Service, Eckental) from the dose-dependent decrease in the writhing reaction, by comparison with mice tested in parallel to which only phenylquinone had been administered. All the compounds according to the invention which were investigated exhibited a pronounced analgesic effect. The results are summarized in the following Table:
TABLE
Writhing inhibition
Compound % Inhibition
according to ED50 25 mg/kg
Example the invention [mg/kg per os] per os
1 (1) 5.8
2 (−1) 22.3
2 (+1) 1.1
3 (2) 13.2
4 (3) −81.3
5 (4) 15.5
6 (5) 8.3
7 (6) 11.8
8 (7) 27.3
9 (8) 12.9
10 (9) 12.8
11 (10) 12.9
13 (12) 19.9
15 (14) 10.5
16 (15) 3.8
17 (+15) −95.2
18 (16) −100.0
19 (−16) 16.1
19 (+16) 1.0
20 (17) −87.0
21 (−17) −58.3
21 (+17) −97.2
22 (+18) 15.7
24 (+21) 1.9
The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Since modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art, the invention should be construed to include all variations within the scope of the appended claims and equivalents thereof.

Claims (147)

What is claimed is:
1. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ia′:
Figure USRE039593-20070424-C00041
X represents OH, F, Cl, H or an OCOR6 group in which R6 is a C1-3-alkyl group;
R1 is a C1-4-alkyl group;
R2 represents H or a C1-4-alkyl group, and
R3 is different from R2 and represents H or a straight chain C1-4-alkyl group, and
R5 represents H, and R4 represents meta-O—Z,
where Z is H, C1-3-alkyl, PO(OC1-4alkyl)2, CO(OC1-5-alkyl), CONH—C6H4—(C1-3-alkyl) or CO—C6H4—R7, in which R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2, where R8 is C1-4-alkyl or 4-morpholino,
or R4 represents meta-S-C1-3-alkyl, meta-Cl, meta-F, meta-CR9R10R11, ortho-OH, ortho-O—C2-3-alkyl, para-F or para-CR9R10R11, where R9, R10 and R11 independently represent H or F, or
R5 represents para-Cl, para-F, para-OH or para-O—C1-3-alkyl, and R4 represents meta-Cl, meta-F, meta-OH or meta-O—C1-3-alkyl, or
R4 and R5 together represent 3,4-OCH═CH— or 3,4-OCH═CHO—; or a salt thereof with a physiologically acceptable acid.
2. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer according to claim 1, wherein
X represents OH, F, Cl or H;
R1 represents a C1-4-alkyl group;
R2 represents H or CH3;
R3 is different from R2 and represents H or CH3, and
R5 represents H, and R4 represents meta-OC1-3-alkyl, meta-OH, meta-S—C1-3-alkyl, meta-F, meta-Cl, meta-CH3, meta-CF2H, meta-CF3 or para-CF3, or
R5 represents para-Cl or para-F, and R4 represents meta-Cl or meta-F, or
R4 and R5 together represent 3,4-OCH═CH—.
3. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer according to claim 1, wherein X represents OH, F, Cl or an OCOR4 group in which R6 is a C1-3-alkyl group.
4. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer according to claim 1, wherein R2 is C1-4-alkyl.
5. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer according to claim 1, wherein R9, R10 and R11 represent F.
6. An isolated 1-phenyl-3-dimethylaminopropane diastereoisomer having a configuration corresponding to the formula Ia,
Figure USRE039593-20070424-C00042
wherein
X represents OH, F, Cl, H or an OCOR6 group in which R6 is a C1-3-alkyl group;
R1 is a C1-4-alkyl group;
R2 represents a C1-4-alkyl group, and
R5 represents H, and R4 represents meta-O—Z,
where Z is H, C1-3-alkyl, PO(OC1-4alkyl)2, CO(OC1-5-alkyl), CONH—C6H4—(C1-3-alkyl) or CO—C6H4—R7, in which R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2, where R8 is C1-4-alkyl or 4-morpholino, or R4 represents meta-S—C1-3-alkyl, meta-Cl, meta-F, meta-CR9R10R11, ortho-OH, ortho-O—C2-3-alkyl, para-F or para-CR9R10R11, where R9, R10 and R11 independently represent H or F, or
R5 represents para-Cl, para-F, para-OH or para-O—C1-3-alkyl, and R4 represents meta-Cl, meta-F, meta-OH or meta-O—C1-3-alkyl, or
R4 and R5 together represent 3,4-OCH═CH— or 3,4-OCH═CHO—;
or a salt thereof with a physiologically acceptable acid.
7. An analgesic composition comprising at least one 1-phenyl-3-dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ia′:
Figure USRE039593-20070424-C00043
wherein
X represents OH, F, Cl, H or an OCOR6 group in which R6 is a C1-3-alkyl group;
R1 is a C1-4-alkyl group;
R2 represents H or a C1-4-alkyl group, and
R3 is different from R2 and represents H or a straight chain C1-4-alkyl group, and
R5 represents H, and R4 represents meta-O—Z,
where Z is H, C1-3-alkyl, PO(OC1-4alkyl)2, CO(OC1-5-alkyl), CONH—C6H4—(C1-3-alkyl) or CO—C6H4—R7, in which R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2, where R8 is C1-4-alkyl or 4-morpholino,
or R4 represents meta-S—C2-3-alkyl, meta-Cl, meta-F, meta-CR9R10R11, ortho-OH, ortho-O—C2-3-alkyl, para-F or para-CR9R10R11, where R9, R10 and R11 independently represent H or F, or
R5 represents para-Cl, para-F, para-OH or para-O—C1-3-alkyl, and R4 represents meta-Cl, meta-F, meta-OH or meta-O—C1-3-alkyl, or
R4 and R5 together represent 3,4-OCH═CH— or 3,4-OCH═CHO—; or a salt thereof with a physiologically acceptable acid, and at least one conventional pharmaceutical carrier or adjuvant.
8. A method of treating a mammal suffering from pain, said method comprising administering to said mammal an effective analgesic amount of a 1-phenyl-3-dimethylaminopropane compound corresponding to formula I
Figure USRE039593-20070424-C00044
wherein
X represents OH, F, Cl, H or an OCOR6 group in which R6 is a C1-3-alkyl group;
R1 is a C1-4-alkyl group;
R2 represents H or a C1-4-alkyl group and R3 represents H or a straight chain C1-4-alkyl group, or R2 and R3 together form a C4-7 cycloalkyl radical, and
R5 represents H, and R4 represents meta-O—Z,
where Z is H, C1-3-alkyl, PO(OC1-4alkyl)2, CO(OC1-5-alkyl), CONH—C6H4—(C1-3-alkyl) or CO—C6H4—R7, in which R7 is ortho-OCOC1-3-alkyl or meta- or para-CH2N(R8)2, where R8 is C1-4-alkyl or 4-morpholino,
or R4 represents meta-S—C1-3-alkyl, meta-Cl, meta-F, meta-CR9R10R11, ortho-OH, ortho-O—C2-3-alkyl, para-F or para-CR9R10R11, where R9, R10 and R11 independently represent H or F, or
R5 represents para-Cl, para-F, para-OH or para-O—C1-3-alkyl, and R4 represents meta-Cl, meta-F, meta-OH or meta-O—C1-3-alkyl, or
R4 and R5 together represent 3,4-OCH═CH— or 3,4-OCH═CHO—, or a salt thereof with a physiologically acceptable acid.
9. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to at least one of formulae Ia′ and Ic′;
Figure USRE039593-20070424-C00045
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group,
R 1 is a C 1-4-alkyl group,
R 2 represents a C n-alkyl group, wherein n=1-4,
R 3 is different from R 2 and represents H or a straight chain C m-alkyl group, wherein 0<m<n, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—,
or a salt thereof with a physiologically acceptable acid.
10. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ia′:
Figure USRE039593-20070424-C00046
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group,
R 1 is a C 1-4-alkyl group,
R 2 represents a C 1-4-alkyl group, and
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group, such that X and the dimethylamino group are disposed threo in relation to each other, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—,
or a salt thereof with a physiologically acceptable acid.
11. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein R 5 is H, and R 4 is meta-OCH 3 .
12. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein R 5 is H, and R 4 is meta-OH.
13. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein
X represents OH, F, Cl, or H;
R 1 is a C 1-4-alkyl group;
R 2 represents CH 3 ;
R 3 is H; and
R 5 represents H, and R 4 represents meta-O—C 1-3-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
14. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein X represents OH, F, Cl, or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
15. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein R 2 is CH 3 , and R 3 is H.
16. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein R 9 , R 10 and R 11 represent F.
17. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein X represents OH.
18. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
19. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein R 5 is H and R 4 is meta-OCH 3 .
20. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein R 5 is H and R 4 is meta-OH.
21. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein X represents OH, F, Cl, or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
22. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein R 9 , R 10 and R 11 represent F.
23. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein X represents OH.
24. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
25. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to at least one of formulae Ia′ and Ic′:
Figure USRE039593-20070424-C00047
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group,
R 1 is a C 1-4-alkyl group,
R 2 represents a C 1-4-alkyl group, and
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group, such that X and the dimethylamino group are disposed threo in relation to each other, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—,
or a salt thereof with a physiologically acceptable acid.
26. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein
X represents OH, F, Cl, or H;
R 1 is a C 1-4-alkyl group;
R 2 represents CH 3 ;
R 3 is H; and
R 5 represents H, and R 4 represents meta-OC 1-3-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
27. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein R 5 is H and R 4 is meta-OCH 3 .
28. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein R 5 is H and R 4 is meta-OH.
29. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein X represents OH, F, Cl or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
30. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein R 2 is CH 3 , and R 3 is H.
31. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein R 9 , R 10 and R 11 represent F.
32. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein X represents OH.
33. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
34. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to at least one of formulae Ia and Ic:
Figure USRE039593-20070424-C00048
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group;
R 1 is a C 1-4-alkyl group;
R 2 represents a C 1-4-alkyl group, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—;
or a salt thereof with a physiologically acceptable acid.
35. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein R 5 is H and R 4 is meta-OCH 3 .
36. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein R 5 is H and R 4 is meta-OH.
37. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein X represents OH, F, Cl or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
38. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein R 9 , R 10 and R 11 represent F.
39. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein X represents OH.
40. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
41. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ic′:
Figure USRE039593-20070424-C00049
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group,
R 1 is a C 1-4-alkyl group,
R 2 represents a C 1-4-alkyl group, and
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group, such that X and the dimethylamino group are disposed threo in relation to each other, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino, or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—,
or a salt thereof with a physiologically acceptable acid.
42. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein
X represents OH, F, Cl, or H;
R 1 is a C 1-4-alkyl group;
R 2 represents CH 3 ;
R 8 is H; and
R 5 represents H, and R 4 represents meta-OC 1-3-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
43. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein R 5 is H and R 4 is meta-OCH 3 .
44. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein R 5 is H and R 4 is meta-OH.
45. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein X represents OH, F, Cl or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
46. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein R 2 is CH 3 , and R 3 is H.
47. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein R 9 , R 10 and R 11 represent F.
48. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein X represents OH.
49. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
50. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ic:
Figure USRE039593-20070424-C00050
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group;
R 1 is a C 1-4-alkyl group;
R 2 represents a C 1-4-alkyl group, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 1-4-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—;
or a salt thereof with a physiologically acceptable acid.
51. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein R 5 is H and R 4 is meta-OCH 3 .
52. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein R 5 is H and R 4 is meta-OH.
53. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein X represents OH, F, Cl or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
54. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein R 9 , R 10 and R 11 represent F.
55. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein X represents OH.
56. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein X represents F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group.
57. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is ( 2S, 3S)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan- 3 -ol hydrochloride (− 1 ).
58. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 2R, 3R)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan- 3 -ol hydrochloride (+ 1 ).
59. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 2R, 3R)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan- 3 -ol hydrochloride (+ 1 ).
60. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 1S,2S)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (+ 21 ).
61. (−)-( 1R,2R)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (− 21 ).
62. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 1RS,2RS)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (+ 21 ).
63. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 2S,3S)-[ 3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (+ 23 ).
64. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (−)-( 2R,3R)-[ 3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (− 23 ).
65. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein the compound is (+)-( 2RS, 3RS)-[3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (+23).
66. An analgesic composition comprising at least one 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to at least one of formulae Ia′ and Ic′:
Figure USRE039593-20070424-C00051
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group;
R 1 is a C 1-4-alkyl group;
R 2 represents a C 1-4-alkyl group, and
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group, such that X and the dimethylamino group are disposed threo in relation to each other, and
R 5 represents H, and R 4 represents meta-O—Z, C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—;
or a salt thereof with a physiologically acceptable acid, and at least one suitable pharmaceutical carrier or adjuvant.
67. An analgesic composition according to claim 66, wherein
X represents OH, F, Cl, or H;
R 1 represents a C 1-4-alkyl group;
R 2 represents CH 3 ;
R 3 is H; and
R 5 represents H, and R 4 represents meta-OC 1-3-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
68. An analgesic composition according to claim 66, wherein R5 is H and R 4 is meta-OCH 3 .
69. An analgesic composition according to claim 66, wherein R5 is H and R 4 is meta-OH.
70. An analgesic composition according to claim 66, wherein X represents OH, F, Cl or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
71. An analgesic composition according to claim 66, wherein R2 is CH 2 , and R 3 is H.
72. An analgesic composition according to claim 66, wherein R9 , R 10 and R 11 represent F.
73. An analgesic composition according to claim 66, wherein X represents OH.
74. An analgesic composition according to claim 66, wherein X represents F, Cl, H or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
75. An analgesic composition according to claim 66, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ia′.
76. An analgesic composition according to claim 66, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ic′.
77. An analgesic composition comprising at least one 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to at least one of formulae Ia and Ic:
Figure USRE039593-20070424-C00052
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group;
R 1 is a C 1-4-alkyl group;
R 2 represents a C 1-4-alkyl group, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 1-4-alkyl)2 , CO(OC1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—;
or a salt thereof with a physiologically acceptable acid, and at least one suitable pharmaceutical carrier or adjuvant.
78. An analgesic composition according to claim 77, wherein R5 is H and R 4 is meta-OCH 3 .
79. An analgesic composition according to claim 77, wherein R5 is H and R 4 is meta-OH.
80. An analgesic composition according to claim 77, wherein X represents OH, F, Cl or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
81. An analgesic composition according to claim 77, wherein R9 , R 10 and R 11 represent F.
82. An analgesic composition according to claim 77, wherein X represents OH.
83. An analgesic composition according to claim 77, wherein X represents F, Cl, H or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
84. An analgesic composition according to claim 77, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ia.
85. An analgesic composition according to claim 77, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ic.
86. A method according to claim 8, wherein
X represents OH, F, Cl, or H;
R 1 represents a C 1-4-alkyl group;
R 2 represents CH 8 ;
R 3 represents H, and
R 5 represents H, and R 4 represents meta-OC 1-8-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
87. A method according to claim 8, wherein R5 is H and R 4 is meta-OCH 8 .
88. An method according to claim 8, wherein R5 is H and R 4 is meta-OH.
89. A method according to claim 8, wherein X represents OH, F, Cl or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
90. A method according to claim 8, wherein R2 is C 1-4-alkyl, and R 3 is different from R 2 and is H or C 1-3 alkyl.
91. A method according to claim 8, wherein R9 , R 10 and R 11 represent F.
92. A method according to claim 8, wherein X represents OH.
93. A method according to claim 8, wherein X represents F, Cl, H or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
94. A method according to claim 8, wherein X represents H.
95. A method according to claim 8, wherein the compound of formula I has a configuration corresponding to at least one of formulae Ia′ and Ic′:
Figure USRE039593-20070424-C00053
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group,
R 1 is a C 1-4-alkyl group,
R 2 represents a C 1-4-alkyl group, and
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group, such that X and the dimethylamino group are disposed threo in relation to each other,
and R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—,
or a salt thereof with a physiologically acceptable acid.
96. A method according to claim 95, wherein
X represents OH, F, Cl, or H;
R 1 represents a C 1-4-alkyl group;
R 2 represents CH 3 ;
R 3 represents H, and
R 5 represents H, and R 4 represents meta-OC 1-3-alkyl, meta-OH, meta-S—C 1-3-alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
97. A method according to claim 95, wherein R5 is H and R 4 is meta-OCH 3 .
98. An method according to claim 95, wherein R5 is H and R 4 is meta-OH.
99. A method according to claim 95, wherein X represents OH, F, Cl or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
100. A method according to claim 95, wherein R2 is CH 3 , and R 3 is H.
101. A method according to claim 95, wherein R9 , R 10 and R 11 represent F.
102. A method according to claim 95, wherein X represents OH.
103. A method according to claim 95, wherein X represents F, Cl, H or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
104. A method according to claim 95, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ia′.
105. A method according to claim 95, wherein the 1-phenyl- 3 -dimethylaminopropane diastereoisomer has a configuration corresponding to formula Ic′.
106. A method according to claim 8, wherein the compound of formula I has a configuration corresponding to at least one of formulae Ia and Ic:
Figure USRE039593-20070424-C00054
wherein
X represents OH, F, Cl, H or an OCOR 6 group in which R 6 is a C 1-3-alkyl group;
R 1 is a C 1-4-alkyl group;
R 2 represents a C 1-4-alkyl group, and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 1-4-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino, or
R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—;
or a salt thereof with a physiologically acceptable acid.
107. A method according to claim 106, wherein X represents OH, F, Cl or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
108. A method according to claim 106, wherein R9 , R 10 and R 11 represent F.
109. A method according to claim 106, wherein X represents OH.
110. A method according to claim 106, wherein X represents F, Cl, H or an OCOR6 group in which R 6 is a C 1-3-alkyl group.
111. A method according to claim 106, wherein the compound is a 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ia.
112. A method according to claim 106, wherein the compound is a 1-phenyl- 3 -dimethylaminopropane diastereoisomer having a configuration corresponding to formula Ic.
113. A method according to claim 106, wherein R5 is H and R 4 is meta-OCH 3 .
114. A method according to claim 106, wherein R5 is H and R 4 is meta-OH.
115. A method according to claim 8, wherein the compound is (+)-( 1RS,2RS)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (+ 21 ).
116. A method according to claim 8, wherein the compound is (+)-( 1S,2S)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (+ 21 ).
117. A method according to claim 8, wherein the compound is (−)-( 1R,2R)- 3 -( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol hydrochloride (− 21 ).
118. A method according to claim 8, wherein the compound is (+)-( 2RS,3RS)-[ 3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (+23 ).
119. A method according to claim 8, wherein the compound is (+)-( 2S,3S)-[ 3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (+ 23 ).
120. A method according to claim 8, wherein the compound is (−)-( 2R,3R)-[ 3 -( 3 -methoxyphenyl)- 2 -methylpentyl]-dimethylamine hydrochloride (− 23 ).
121. A method according to claim 8, wherein the compound is (+)-( 2RS, 3RS)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan-3-ol hydrochloride (+ 1 ).
122. A method according to claim 8, wherein the compound is (+)-( 2R, 3R)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan-3-ol hydrochloride (+ 1 ).
123. A method according to claim 8, wherein the compound is (−)-( 2S, 3S)- 1 -dimethylamino- 3 -( 3 -methoxyphenyl)- 2 -methylpentan-3-ol hydrochloride (− 1 ).
124. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 6 , wherein X is H.
125. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 10 , wherein X is H.
126. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 25 , wherein X is H.
127. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 34 , wherein X is H.
128. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 41 , wherein X is H.
129. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 50 , wherein X is H.
130. An analgesic composition according to claim 66, wherein X is H.
131. An analgesic composition according to claim 75, wherein X is H.
132. An analgesic composition according to claim 76, wherein X is H.
133. An analgesic composition according to claim 77, wherein X is H.
134. An analgesic composition according to claim 84, wherein X is H.
135. An analgesic composition according to claim 85, wherein X is H.
136. A method according to claim 86, wherein X is H.
137. A method according to claim 95, wherein X is H.
138. A method according to claim 106, wherein X is H.
139. A method according to claim 113, wherein X is H.
140. A method according to claim 114, wherein X is H.
141. An isolated 1-phenyl- 3 -dimethylaminopropane diastereomer having a configuration corresponding to formula I:
Figure USRE039593-20070424-C00055
wherein
X represents H,
R 1 is a C 1-4-alkyl group,
R 2 represents a C 1-4-alkyl group,
R 3 is different from R 2 and represents H or a straight chain C 1-3-alkyl group,
and
R 5 represents H, and R 4 represents meta-O—Z,
where Z is H, C 1-3-alkyl, PO(OC 14-alkyl)2 , CO(OC 1-5-alkyl), CONH—C 6 H 4—(C 1-3-alkyl) or CO—C 6 H 4 —R 7 , in which R 7 is ortho-OCOC 1-3-alkyl or meta- or para-CH 2 N(R 8)2 , where R 8 is C 1-4-alkyl or 4 -morpholino,
or R 4 represents meta-S—C 1-3-alkyl, meta-Cl, meta-F, meta-CR 9 R 10 R 11 , ortho-OH, ortho-O—C 2-3-alkyl, para-F or para-CR 9 R 10 R 11 , where R 9 , R 10 and R 11 independently represent H or F, or
R 5 represents para-Cl, para-F, para-OH or para-O—C 1-3-alkyl, and R 4 represents meta-Cl, meta-F, meta-OH or meta-O—C 1-3-alkyl, or
R 4 and R 5 together represent 3,4 -OCH═CH— or 3,4 -OCH═CHO—, and
wherein carbon atoms at positions 1 and 2 are both asymmetric carbons and the diastereomer has a ( 1R, 2R) or ( 1S, 2S) configuration,
or a salt thereof with a physiologically acceptable acid.
142. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 141 , wherein R 5 is H, and R 4 is meta-OCH 3 .
143. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 141 , wherein R 5 is H, and R 4 is meta-OH.
144. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 141 , wherein
R 2 represents CH 3 ;
R 3 is H; and
R 5 represents H, and R 4 represents meta-O—C 1-3-alkyl, meta-OH, meta-S—1-3 -alkyl, meta-F, meta-Cl, meta-CH 3 , meta-CF 2 H, meta-CF 3 , or para-CF 3 , or
R 5 represents para-Cl, or para-F, and R 4 represents meta-Cl, or meta-F, or
R 4 and R 5 together represent 3,4 -OCH═CH—.
145. An isolated 1-phenyl- 3 -dimethylaminopropane diastereoisomer according to claim 141 , wherein R 2 is CH 3 , and R 3 is H.
146. An isolated 1-phenyl- 3 -dimethylaminopropane diastereomer according to claim 141 , wherein R 9 , R 10 and R 11 represent F.
147. A pharmaceutically acceptable salt of (−)-( 1R,2R)- 3R-( 3 -dimethylamino- 1 -ethyl- 2 -methylpropyl)-phenol.
US10/462,844 1994-07-23 2003-06-17 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects Expired - Lifetime USRE39593E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/462,844 USRE39593E1 (en) 1994-07-23 2003-06-17 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4426245 1994-07-23
DE4426245A DE4426245A1 (en) 1994-07-23 1994-07-23 1-phenyl-3-dimethylamino-propane compounds with pharmacological activity
US08/466,911 US6248737B1 (en) 1994-07-23 1995-06-06 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US10/462,844 USRE39593E1 (en) 1994-07-23 2003-06-17 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/466,911 Reissue US6248737B1 (en) 1994-07-23 1995-06-06 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects

Publications (1)

Publication Number Publication Date
USRE39593E1 true USRE39593E1 (en) 2007-04-24

Family

ID=6524045

Family Applications (3)

Application Number Title Priority Date Filing Date
US08/466,911 Ceased US6248737B1 (en) 1994-07-23 1995-06-06 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US09/838,192 Expired - Lifetime US6344558B1 (en) 1994-07-23 2001-04-20 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect
US10/462,844 Expired - Lifetime USRE39593E1 (en) 1994-07-23 2003-06-17 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US08/466,911 Ceased US6248737B1 (en) 1994-07-23 1995-06-06 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
US09/838,192 Expired - Lifetime US6344558B1 (en) 1994-07-23 2001-04-20 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effect

Country Status (31)

Country Link
US (3) US6248737B1 (en)
EP (1) EP0693475B1 (en)
JP (2) JP4034366B2 (en)
KR (1) KR100364465B1 (en)
CN (1) CN1077566C (en)
AT (1) ATE163176T1 (en)
AU (1) AU685644B2 (en)
BR (1) BR9502390A (en)
CA (1) CA2154424C (en)
CO (1) CO4410179A1 (en)
CZ (1) CZ286441B6 (en)
DE (3) DE4426245A1 (en)
DK (1) DK0693475T3 (en)
ES (1) ES2115298T3 (en)
FI (1) FI114704B (en)
FR (1) FR12C0016I2 (en)
GR (1) GR3026326T3 (en)
HK (1) HK1005062A1 (en)
HU (1) HU218481B (en)
IL (1) IL113901A (en)
LT (1) LTPA2011007I1 (en)
LU (1) LU91793I2 (en)
MY (1) MY114889A (en)
NZ (1) NZ272623A (en)
PE (1) PE34896A1 (en)
PL (1) PL181169B1 (en)
RU (1) RU2150465C1 (en)
SI (1) SI0693475T1 (en)
UA (1) UA41345C2 (en)
UY (1) UY23992A1 (en)
ZA (1) ZA956118B (en)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060188447A1 (en) * 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US20080247959A1 (en) * 2003-08-06 2008-10-09 Grunenthal Gmbh Form of administration secured against misuse
US20080311187A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US20080317854A1 (en) * 2004-04-22 2008-12-25 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
WO2010096045A1 (en) 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US20100297229A1 (en) * 2007-11-23 2010-11-25 Nectid Inc. Tapentadol compositions
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
WO2011107876A2 (en) 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011128784A2 (en) 2010-04-05 2011-10-20 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
WO2012101649A1 (en) 2011-01-27 2012-08-02 Symed Labs Limited A novel stereospecific synthesis of (-) (2s,3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
US8552219B2 (en) 2010-09-20 2013-10-08 Ind-Swift Laboratories Limited Process for preparing L-phenyl-3-dimethylaminopropane derivative
US8618177B2 (en) 2002-11-22 2013-12-31 Gruenenthal Gmbh Method of treating pain caused by inflammation
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
WO2015075678A1 (en) 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
WO2016190766A1 (en) 2015-05-26 2016-12-01 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EP3287447A1 (en) 2010-07-23 2018-02-28 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US9914695B2 (en) 2015-07-10 2018-03-13 Mallinckrodt Llc Two-step process for preparing 3-substituted phenylalkylamines
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
WO2019238267A1 (en) 2018-06-15 2019-12-19 Pharmathen S.A. A novel process for the preparation of tapentadol
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710575B2 (en) * 1994-02-08 1999-09-23 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
FR2745815B1 (en) * 1996-03-08 1998-06-26 Synthelabo BENZOFURANE DERIVATIVES, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME
AU2030197A (en) * 1996-03-08 1997-09-22 Synthelabo 2-aminoethyl-benzofuran derivatives, preparation thereof and therapeutical use thereof
DE19609847A1 (en) * 1996-03-13 1997-09-18 Gruenenthal Gmbh Dimethyl- (3-aryl-but-3-enyl) amine compounds as active pharmaceutical ingredients
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
DE19933421A1 (en) 1999-07-16 2001-01-25 Gruenenthal Gmbh 2-benzyl-3-dimethylamino-1-phenyl propane derivative
PE20010623A1 (en) * 1999-10-05 2001-07-07 Gruenenthal Chemie USE OF (+) - TRAMADOL AND / OR O-DEMETILTRAMADOL FOR TREATMENT OF INCREASED URINARY URGENCY AND / OR URINARY INCONTINENCE
DE10000312A1 (en) * 2000-01-05 2001-07-12 Gruenenthal Gmbh Substituted aminomethyl phenyl cyclohexane derivatives
DE10059412A1 (en) * 2000-11-30 2002-06-13 Gruenenthal Gmbh Use of 1-phenyl-3-dimethylamino-propane compounds for the treatment of urinary incontinence
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (en) * 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmaceutical salts
DE10146275A1 (en) * 2001-09-18 2003-04-24 Gruenenthal Gmbh Combination of selected opioids with muscarinic antagonists for the treatment of urinary incontinence
PE20030527A1 (en) * 2001-10-24 2003-07-26 Gruenenthal Chemie DELAYED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING 3- (3-DIMETHYLAMINO-1-ETHYL-2-METHYL-PROPYL) PHENOL OR A PHARMACEUTICALLY ACCEPTABLE SALT OF THE SAME AND ORAL TABLETS CONTAINING IT
US20080057011A1 (en) * 2001-12-12 2008-03-06 L'oreal S.A., Composition structured with a polymer containing a heteroatom and an Organogelator
DE10161644A1 (en) * 2001-12-14 2003-06-26 Gruenenthal Gmbh New N,N'-disubstituted piperazine derivatives are noradrenaline reuptake inhibitors, useful e.g. for the treatment of arrhythmia, emesis, diarrhea, inflammation or especially depression or pain
DE10161809A1 (en) * 2001-12-14 2003-06-26 Gruenenthal Gmbh Pharmaceutical compositions, useful e.g. for the treatment of neurodegenerative diseases, psychiatric or neuropathological diseases or especially pain and epilepsy, comprise N,N'-disubstituted piperazine derivatives
DE10163421A1 (en) * 2001-12-21 2003-07-31 Gruenenthal Gmbh Use of (+) - (1S, 2S) -3- (3-dimethylamino-1-ethyl-2-methyl-propyl) phenol as an anti-emetic
US20050137194A1 (en) * 2002-05-29 2005-06-23 Gruenenthal Gmbh Combination of selected opioids with other active compounds for treatment of urinary incontinence
US7410965B2 (en) * 2002-05-29 2008-08-12 Gruenenthal Gmbh Delayed release pharmaceutical composition containing 1-dimethyl-amino-3-(3-methoxyphenyl)-2-methyl-pentan-3-ol
DE10224108A1 (en) * 2002-05-29 2004-01-29 Grünenthal GmbH 1-Dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol containing sustained-release drug
US20050137145A1 (en) * 2002-05-30 2005-06-23 Gruenenthal Gmbh Metabolites of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and their use in the treatment of urinary incontinence
DE10224624A1 (en) * 2002-05-30 2003-12-11 Gruenenthal Gmbh Metabolites and prodrugs of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol
DE10224556A1 (en) * 2002-05-31 2004-01-08 Grünenthal GmbH Medicament containing 1-dimethylamino-3- (3-methoxy-phenyl) 2-methyl-pentan-3-ol in various formulations
US7550624B2 (en) * 2002-06-06 2009-06-23 Gruenenthal Gmbh Pharmaceutically active salts and esters of 1-dimethylamino-3-(3-methoxyphenyl)-2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl)-phenol and methods of using same
DE10225315A1 (en) * 2002-06-06 2003-12-24 Gruenenthal Gmbh Active substance salts and esters of 1-dimethylamino-3- (3-methoxyphenyl) -2-methylpentan-3-ol and 3- (3-dimethylamino-1-ethyl-1-hydroxy-2-methylpropyl) - phenol
DE10228192A1 (en) * 2002-06-24 2004-01-15 Grünenthal GmbH Dosage form for oral administration of active ingredients, vitamins and / or nutrients
WO2004028451A2 (en) * 2002-09-24 2004-04-08 Virginia Commonwealth University β-HYDROXYPHENYLALKYLAMINES AND THEIR USE FOR TREATING GLAUCOMA
DE10326097A1 (en) * 2003-06-06 2005-01-05 Grünenthal GmbH Process for the preparation of dimethyl (3-aryl-butyl) -amine compounds
DE10328316A1 (en) 2003-06-23 2005-01-20 Grünenthal GmbH Process for the preparation of dimethyl (3-aryl-butyl) -amine compounds as pharmaceutical active ingredients
DE102004032051A1 (en) * 2004-07-01 2006-01-19 Grünenthal GmbH Process for the preparation of a secured against misuse, solid dosage form
US8075872B2 (en) * 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
DE102004019916A1 (en) * 2004-04-21 2005-11-17 Grünenthal GmbH Anti-abuse drug-containing patch
EA013261B1 (en) * 2004-05-14 2010-04-30 Янссен Фармацевтика, Н.В. Carboxamido opioid compounds
SI1612203T1 (en) * 2004-06-28 2007-12-31 Gruenenthal Chemie Crystalline forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride
JP2008527035A (en) * 2005-01-18 2008-07-24 ユニヴァーシテイ オブ フロリダ Compositions and methods for inhibiting pain
US20060160905A1 (en) * 2005-01-18 2006-07-20 Bergeron Raymond J Jr Compositions and methods for inhibiting pain
DE102005033732B4 (en) * 2005-05-27 2014-02-13 Grünenthal GmbH Separation of stereoisomeric N, N-dialkylamino-2-alkyl-3-hydroxy-3-phenyl-alkanes
DE202005014347U1 (en) * 2005-09-09 2007-01-18 Grünenthal GmbH Application system for an active-ingredient release system, comprises a film-forming transparent plastic foil strip detachably connected to plaster containing an active ingredient and to controlled-release agent for the active ingredient
US20090104266A1 (en) * 2005-09-15 2009-04-23 Tobias Jung 3-(2-dimethylaminomethylcy clohexyl)phenol retard formulation
DE102005052588A1 (en) * 2005-11-02 2007-05-10 Grünenthal GmbH Process for the preparation of substituted dimethyl- (3-aryl-butyl) -amine compounds by means of homogeneous catalysis
US20070254960A1 (en) * 2006-04-28 2007-11-01 Gruenenthal Gmbh Pharmaceutical combination
WO2007128413A1 (en) * 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
SI2012763T1 (en) * 2006-04-28 2011-06-30 Gruenenthal Gmbh Pharmaceutical combination comprising 3- (3-dimethylamin0-1-ethyl-2-methyl-pr0pyl) -phenol and an nsaid
TWI401237B (en) * 2006-07-24 2013-07-11 Preparation of 3-[(1r, 2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol monohydrochloride
CN101495447B (en) * 2006-07-24 2013-05-29 詹森药业有限公司 Preparation of (2R,3R)-3-(3-methoxyphenyl)-N,N,2-trimethylpentanamine
TWI496762B (en) * 2006-07-24 2015-08-21 Process for the preparation of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
DE102007012165A1 (en) 2007-03-12 2008-09-18 Grünenthal GmbH Use of 1-phenyl-3-dimethylamino-propane compounds for the therapy of neuropathy pain
DE102007019417A1 (en) * 2007-04-23 2008-11-13 Grünenthal GmbH Tapentadol for the treatment of pain in osteoarthritis
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
US20090076164A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched tapentadol
PT3173400T (en) * 2007-12-07 2019-12-13 Gruenenthal Gmbh Medicaments containing crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
BRPI0920521A2 (en) 2008-09-05 2018-01-16 Gruenenthal Gmbh pharmaceutical combination
EP2424514B1 (en) 2009-04-30 2017-02-22 Grünenthal GmbH Tapentadol for treating rheumatoid arthritic pain
CN102002065B (en) * 2009-09-02 2014-09-10 上海特化医药科技有限公司 Method for preparing tapentadolhydrochloride and intermediate thereof
US8288592B2 (en) 2009-09-22 2012-10-16 Actavis Group Ptc Ehf Solid state forms of tapentadol salts
IT1397189B1 (en) 2009-12-01 2013-01-04 Archimica Srl NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES.
AU2010337825A1 (en) 2009-12-29 2012-07-05 Mapi Pharma Limited Intermediate compounds and processes for the preparation of tapentadol and related compounds
WO2011080756A1 (en) * 2009-12-29 2011-07-07 Ind-Swift Laboratories Limited Process for the preparation of 1-phenyl-3-dimethylaminopropane derivatives
WO2011092719A2 (en) * 2010-02-01 2011-08-04 Ind-Swift Laboratories Limited Process for the preparation of l-phenyl-3-dimethylaminopropane derivatives
EP2383255A1 (en) 2010-04-28 2011-11-02 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
US20130116333A1 (en) 2010-05-05 2013-05-09 Ratiopharm Gmbh Solid tapentadol in non-crystalline form
ITMI20100924A1 (en) * 2010-05-21 2011-11-22 Fidia Farmaceutici NEW METHOD OF SYNTHESIS OF THE TWO TAPENTADOL ENANTIOMERIC FORMS
US8669399B2 (en) 2010-06-15 2014-03-11 Grünenthal GmbH Process for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
EP2992877A1 (en) 2010-06-15 2016-03-09 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
PT2588093T (en) 2010-06-30 2016-09-21 Gruenenthal Gmbh Tapentadol for use in the treatment of irritable bowel syndrome
IT1401109B1 (en) 2010-07-02 2013-07-12 Archimica Srl NEW PROCESS FOR THE PREPARATION OF TAPENTADOL AND ITS INTERMEDIATES.
EP2606030B1 (en) 2010-08-16 2016-05-18 Indoco Remedies Limited Process for the preparation of tapentadol
CN101948397A (en) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 Method for preparing important intermediate of tapentadol hydrochloride analgesic
WO2012051246A1 (en) 2010-10-12 2012-04-19 Ratiopharm Gmbh Tapentadol hydrobromide and crystalline forms thereof
CZ2010995A3 (en) * 2010-12-30 2012-04-11 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(3-hydroxyphenyl)-2-methylpentylamine
CZ302992B6 (en) * 2010-12-30 2012-02-08 Zentiva, K.S. Process for preparing (2R,3R)-N,N-dimethyl-3-(hydroxyphenyl)-2-methylpentylamine (tapentadol)
CN102617501A (en) * 2011-01-31 2012-08-01 中国科学院上海药物研究所 Substituted valeramide compound, preparation method and application thereof
SI3287123T1 (en) 2011-03-04 2020-07-31 Gruenenthal Gmbh Aqueous pharmaceutical formulation of tapentadol for oral administration
SI2680833T1 (en) 2011-03-04 2016-06-30 Gruenenthal Gmbh Parenteral administration of tapentadol
ES2654407T3 (en) 2011-03-04 2018-02-13 Grünenthal GmbH Semi-solid aqueous pharmaceutical composition containing tapentadol
LT2694049T (en) 2011-04-05 2018-12-27 GrĆ¼nenthal GmbH Tapentadol for preventing chronification of pain
PT2694050T (en) 2011-04-05 2019-11-22 Gruenenthal Gmbh Tapentadol for use in treating pain associated with trigeminal neuralgia
CN102206164A (en) * 2011-04-11 2011-10-05 中国药科大学 Method for preparing tapentadol intermediate
ES2646363T3 (en) 2011-04-29 2017-12-13 Grünenthal GmbH Tapentadol for the prevention and treatment of depression and anxiety
EP2530072A1 (en) 2011-06-03 2012-12-05 Lacer, S.A. New compounds, synthesis and use thereof in the treatment of pain
EP2753302B1 (en) 2011-07-20 2018-11-28 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol
US8895623B2 (en) 2011-07-29 2014-11-25 Gruenenthal Gmbh Intrathecal or epidural administration of 3-[(1S,25)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol
US8853393B2 (en) 2011-07-29 2014-10-07 Anhui New Star Pharmaceutical Development Co., Ltd. Intermediate for preparing tapentadol or analogues thereof
WO2013105109A1 (en) 2011-11-09 2013-07-18 Indoco Remedies Limited Process for the preparation of tapentadol
US20130150622A1 (en) 2011-12-12 2013-06-13 Boehringer Ingelheim International Gmbh Stereoselective synthesis of tapentadol and its salts
CN102557851B (en) * 2011-12-13 2014-03-26 安徽省新星药物开发有限责任公司 New method for synthesizing tapentadol hydrochloride and analogue of tapentadol hydrochloride
WO2013111161A2 (en) * 2012-01-10 2013-08-01 Msn Laboratories Limited Process for the preparation of 3-aryl-2-methyl-propanamine derivatives and polymorphs thereof
WO2013120466A1 (en) 2012-02-17 2013-08-22 Zentiva, K.S. A new solid form of tapentadol and a method of its preparation
EP2674414A1 (en) 2012-06-15 2013-12-18 Siegfried AG Method for the preparation of 1-aryl-1-alkyl-3-dialkylaminopropane compounds
CN103159633B (en) * 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 The preparation method of tapentadol hydrochloride and the compound for the preparation of tapentadol hydrochloride
HUE035512T2 (en) 2012-07-16 2018-05-02 Gruenenthal Gmbh Pharmaceutical patch for transdermal administration of tapentadol
CZ304576B6 (en) * 2012-07-24 2014-07-16 Zentiva, K.S. TAPENTADOL oxalate and process for preparing thereof
KR20150075408A (en) 2012-11-01 2015-07-03 토렌트 파마슈티칼스 리미티드 Pharmaceutical composition of tapentadol for parenteral administration
US9090539B2 (en) 2013-05-24 2015-07-28 Ampac Fine Chemicals Llc Compounds and methods for preparing substituted 3-(1-amino-2-methylpentane-3-yl)phenyl compounds
EP2808319A1 (en) 2013-05-31 2014-12-03 Arevipharma GmbH 3-[3-(Dimethylamino)-1-ethyl-2-methylpropyl]phenol resin complex
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
AU2014351327A1 (en) * 2013-11-01 2016-05-19 Sun Pharma Advanced Research Company Novel intermediate of tapentadol
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
EP3083551B1 (en) 2013-12-16 2018-02-14 Farma GRS, d.o.o. Crystalline form of tapentadol intermediate
CN104803861B (en) * 2014-01-27 2017-05-24 上海博邦医药科技有限公司 Method for synthesizing tapentadol hydrochloride
CZ307492B6 (en) 2014-02-04 2018-10-17 Zentiva, K.S. A solid form of tapentadol maleate and a method of its preparation
GB2523089A (en) * 2014-02-12 2015-08-19 Azad Pharmaceutical Ingredients Ag Stable polymorph form B of tapentadol hydrochloride
EP2942054A1 (en) 2014-05-09 2015-11-11 G.L. Pharma GmbH Slow-release pharmaceutical formulation
BR112017000417B1 (en) 2014-07-10 2021-06-08 SpecGx LLC process for preparing substituted phenylalkanes
PT3273953T (en) 2015-03-27 2019-04-01 Gruenenthal Gmbh Stable formulation for parenteral administration of tapentadol
US10421050B2 (en) * 2015-05-22 2019-09-24 Digi-Star, Llc Utilization of a mobile agricultural weighing system to monitor and store ancillary operational data for diagnostic purposes on trailed and truck-mounted equipment
DK3377049T3 (en) 2015-11-17 2021-04-12 Msn Laboratories Private Ltd Crystalline forms of tapentadol salts and process for preparation thereof
ES2937740T3 (en) 2016-04-19 2023-03-30 Ratiopharm Gmbh Crystalline tapentadol phosphate
EA201990744A1 (en) 2016-09-23 2019-08-30 Грюненталь Гмбх STABLE MEDICINAL FORM FOR Parenteral Administration of TAPENTADOL
HRP20240030T1 (en) 2017-01-11 2024-03-29 Torrent Pharmaceuticals Limited Tapentadol nasal composition
US10292948B2 (en) 2017-01-11 2019-05-21 Torrent Pharmaceuticals Limited Tapentadol nasal composition
WO2019195775A1 (en) * 2018-04-06 2019-10-10 Flex Pharma, Inc. Tolperisone analogs and methods of use
GR1009751B (en) 2019-03-22 2020-05-29 "Φαρματεν Α.Β.Ε.Ε." Prolonged-release oxalic tapentadol -containing formula and preparation method thereof
GR1009791B (en) 2019-03-26 2020-08-03 Φαρματεν Α.Β.Ε.Ε. Prolonged release tapentadol-containing formula - preparation method thereof
KR102297806B1 (en) * 2019-11-11 2021-09-03 한국생산기술연구원 Manufacturing method of Ta-Cu alloy and Ta-Cu alloy using thereof
CN111056961A (en) * 2019-11-13 2020-04-24 李晓强 Preparation method of 3- ((1S,2S) -3-dimethylamino-1-ethyl-2-methylpropyl) phenol hydrochloride
EP3875080A1 (en) 2020-03-02 2021-09-08 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
EP3875077B1 (en) 2020-03-02 2023-12-13 Grünenthal GmbH Dosage form providing prolonged release of tapentadol phosphoric acid salt
PE20230105A1 (en) 2020-03-02 2023-01-25 Gruenenthal Chemie DOSAGE FORM PROVIDING SUPPORTED RELEASE OF TAPENTADOL PHOSPHORIC ACID SALT
DE202020104285U1 (en) 2020-07-24 2020-12-18 Grünenthal GmbH Ethyl cellulose-coated particles containing a salt of tapentadol and phosphoric acid
DE202020005470U1 (en) 2020-11-10 2022-01-25 Grünenthal GmbH Extended-release dosage forms of a salt of tapentadol with L-(+)-tartaric acid
EP3995135B1 (en) 2020-11-10 2022-07-13 Grünenthal GmbH Prolonged release dosage form of tapentadol l-(+)- tartaric acid salt
PE20240113A1 (en) 2020-11-10 2024-01-22 Gruenenthal Chemie SUSTAINED RELEASE DOSAGE FORMS OF A SALT OF TAPENTADOL WITH L-(+)-TARTARIC ACID
EP4011369A1 (en) 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate
EP4269384A1 (en) 2022-04-26 2023-11-01 KRKA, d.d., Novo mesto Method for crystallizing tapentadol intermediate, tapentadol intermediate of high purity, method of making tapentadol and tapentadol of high purity

Citations (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE124521C (en)
US2662886A (en) 1949-01-28 1953-12-15 Winthrop Stearns Inc Substituted phenylpropylamines
DE1051281B (en) 1955-07-05 1959-02-26 Bayer Ag Process for the preparation of derivatives of 1-aryl-3-aminopropan-1-ols
US3328249A (en) 1965-06-21 1967-06-27 Sterling Drug Inc Process for counteracting depressive states
DE2412798A1 (en) 1973-03-19 1974-09-26 Takeda Chemical Industries Ltd NEW PHENYLPROPYLAMINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
US4285961A (en) 1977-07-20 1981-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Basic thioethers
US4336269A (en) 1979-12-10 1982-06-22 Eli Lilly And Company Para-nitrophenylalkylamines
US4404222A (en) 1980-08-25 1983-09-13 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby
DE3242922A1 (en) 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen PHENYLPROPANOLAMINE, THEIR PRODUCTION AND USE
EP0176049A2 (en) 1984-09-28 1986-04-02 Consiglio Nazionale Delle Ricerche Aminoalkylnaphtalene derivatives having pharmacological activities
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4843160A (en) 1984-10-01 1989-06-27 The Dow Chemical Company Preparation of alpha-aminoalkylphenols
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
US5059422A (en) 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5135955A (en) 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
US5169633A (en) 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
US5281623A (en) 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
US5310756A (en) 1989-05-26 1994-05-10 Novo Nordisk A/S Aryloxyphenylpropylamines and their calcium overload blocking compositions and methods of use
US5322859A (en) 1993-02-08 1994-06-21 University Of Iowa Research Foundation Antiglaucoma drug composition and method
US5387614A (en) 1993-07-27 1995-02-07 University Of Iowa Research Foundation Use of sigma receptor ligands as salivary gland stimulants
WO1995021612A2 (en) 1993-02-08 1995-08-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5552439A (en) 1990-08-27 1996-09-03 Eli Lilly And Company Method of treating inflammatory bowel disease
US5587398A (en) 1994-06-03 1996-12-24 David R. Elmaleh Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US5663283A (en) 1991-11-01 1997-09-02 Canon Kabushiki Kaisha Polyamide, electrophotographic photosensitive member employing the polyamide, and electrophotographic apparatus, device unit and facsimile machine employing the member
US5811582A (en) 1996-03-13 1998-09-22 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients
US5830509A (en) 1996-02-07 1998-11-03 West; Daniel David Microparticle complexes with 2-amino-1-phenylpropanol materials
US5981599A (en) 1996-05-01 1999-11-09 Nps Pharmaceuticals, Inc. Inorganic ion receptor active compounds
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6017965A (en) 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6022894A (en) 1996-04-09 2000-02-08 Nps Pharmaceuticals, Inc. Method of using calcilytic compounds
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6051610A (en) 1993-02-08 2000-04-18 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6057371A (en) 1989-12-28 2000-05-02 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
USRE37355E1 (en) 1995-07-11 2001-09-04 Gruenenthal Gmbh 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
US6410790B1 (en) 1999-04-07 2002-06-25 Gruenenthal Gmbh 3-amin3-arylpropan-1-ol compounds, their preparation and use
US20020115725A1 (en) 2000-11-01 2002-08-22 Mel Epstein Methods and compositions for regulating memory consolidation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD124521A1 (en) 1976-03-16 1977-03-02
SE8800207D0 (en) * 1988-01-22 1988-01-22 Kabivitrum Ab NEW AMINES, THEIR USE AND MANUFACTURING
WO1990002126A1 (en) 1988-08-24 1990-03-08 Mochida Pharmaceutical Co., Ltd. Hydantoin derivatives
US6052610A (en) * 1998-01-09 2000-04-18 International Business Machines Corporation Magnetic catheter tracker and method therefor

Patent Citations (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE124521C (en)
US2662886A (en) 1949-01-28 1953-12-15 Winthrop Stearns Inc Substituted phenylpropylamines
DE1051281B (en) 1955-07-05 1959-02-26 Bayer Ag Process for the preparation of derivatives of 1-aryl-3-aminopropan-1-ols
US3328249A (en) 1965-06-21 1967-06-27 Sterling Drug Inc Process for counteracting depressive states
DE2412798A1 (en) 1973-03-19 1974-09-26 Takeda Chemical Industries Ltd NEW PHENYLPROPYLAMINE DERIVATIVES AND PROCESS FOR THEIR PRODUCTION
US4608391A (en) 1977-07-05 1986-08-26 Cornell Research Foundation Inc. Catecholamine derivatives, a process for their preparation and pharmaceutical compositions thereof
US4285961A (en) 1977-07-20 1981-08-25 Merck Patent Gesellschaft Mit Beschrankter Haftung Basic thioethers
US4336269A (en) 1979-12-10 1982-06-22 Eli Lilly And Company Para-nitrophenylalkylamines
US4404222A (en) 1980-08-25 1983-09-13 American Cyanamid Company Phenylethanolamine derivatives and acid addition salts thereof for enhancing the growth rate of meat-producing animals and improving the efficiency of feed utilization thereby
DE3242922A1 (en) 1982-11-20 1984-05-24 Basf Ag, 6700 Ludwigshafen PHENYLPROPANOLAMINE, THEIR PRODUCTION AND USE
EP0176049A2 (en) 1984-09-28 1986-04-02 Consiglio Nazionale Delle Ricerche Aminoalkylnaphtalene derivatives having pharmacological activities
US4843160A (en) 1984-10-01 1989-06-27 The Dow Chemical Company Preparation of alpha-aminoalkylphenols
US5059422A (en) 1985-07-29 1991-10-22 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US5169633A (en) 1985-07-29 1992-12-08 American Cyanamid Company Continuous release phenylethanolamine derivative compositions
US4857553A (en) 1987-08-06 1989-08-15 A. H. Robins Company, Incorporated Method of treating nausea and vomiting with certain substituted-phenylalkylamino (and aminoacid) derivatives and other serotonin depleting agents
US5135955A (en) 1988-04-25 1992-08-04 Eli Lilly And Company Propanamine derivatives
US5310756A (en) 1989-05-26 1994-05-10 Novo Nordisk A/S Aryloxyphenylpropylamines and their calcium overload blocking compositions and methods of use
US6057371A (en) 1989-12-28 2000-05-02 Virginia Commonwealth University Sigma receptor ligands and the use thereof
US5281623A (en) 1990-08-27 1994-01-25 Eli Lilly And Company Method for treating inflammation
US5552439A (en) 1990-08-27 1996-09-03 Eli Lilly And Company Method of treating inflammatory bowel disease
US5280046A (en) 1991-02-22 1994-01-18 The University Of Colorado Foundation, Inc. Method of treating type I diabetes
US6001884A (en) 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5663283A (en) 1991-11-01 1997-09-02 Canon Kabushiki Kaisha Polyamide, electrophotographic photosensitive member employing the polyamide, and electrophotographic apparatus, device unit and facsimile machine employing the member
US6071970A (en) 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6051610A (en) 1993-02-08 2000-04-18 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
WO1995021612A2 (en) 1993-02-08 1995-08-17 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6017965A (en) 1993-02-08 2000-01-25 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US5322859A (en) 1993-02-08 1994-06-21 University Of Iowa Research Foundation Antiglaucoma drug composition and method
US5387614A (en) 1993-07-27 1995-02-07 University Of Iowa Research Foundation Use of sigma receptor ligands as salivary gland stimulants
US5587398A (en) 1994-06-03 1996-12-24 David R. Elmaleh Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor
US6211244B1 (en) 1994-10-21 2001-04-03 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
USRE37355E1 (en) 1995-07-11 2001-09-04 Gruenenthal Gmbh 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
US5648541A (en) 1995-09-28 1997-07-15 Nps Pharmaceuticals, Inc. Chiral reductions of imines leading to the syntheses of optically active amines
US5830509A (en) 1996-02-07 1998-11-03 West; Daniel David Microparticle complexes with 2-amino-1-phenylpropanol materials
US5811582A (en) 1996-03-13 1998-09-22 Gruenenthal Gmbh Dimethyl-(3-aryl-but-3-enyl)-amine compounds as pharmaceutical active ingredients
US6022894A (en) 1996-04-09 2000-02-08 Nps Pharmaceuticals, Inc. Method of using calcilytic compounds
US5981599A (en) 1996-05-01 1999-11-09 Nps Pharmaceuticals, Inc. Inorganic ion receptor active compounds
US6011066A (en) 1998-02-02 2000-01-04 Veterans General Hospital-Taipei Method for treating septic shock
US6410790B1 (en) 1999-04-07 2002-06-25 Gruenenthal Gmbh 3-amin3-arylpropan-1-ol compounds, their preparation and use
US20020115725A1 (en) 2000-11-01 2002-08-22 Mel Epstein Methods and compositions for regulating memory consolidation

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
A. Antoniadou-Vyza et al., "Synthèse Des Phènylalkylamines Encombrés" Chimika Chronika, New Series, 14, (1985) pp. 79-88.
Bundgaard et al., "A Novel Solution-Stable, Water Soluble Prodrug Type for Drugs Containing A Hydroxyl or an HG-Acidic Group", J. Med. Chem., 32, pp. 2503-2507 (1989).
Bundgaard, "Novel Chemical Approaches in Prodrug Design", Drugs of the Future, 16, pp. 443-458, (1991).
Burwell, "The Cleavage of Ethers", Chem. Rev., 54, pp. 615-685 (1954).
Chem. Abstr., 54, 2093c (1960).
Chem. Abstr., 63, p. 6912e (1965).
Ditter et al., "Acetaminophen Prodrugs I", J. Pharm. Sci., 57, pp. 774-780 (1968).
Goodman & Gilman, The Pharmacological Basis of Therapeutics, Pergamon Press, New York (1990).
H. H. Ong et al., "Photocyclizations. III. Synthesis of 3,6-Dimethyl-8-hydroxy-3,4,5,6-tetrahydro-3-benzazocin-2(1H)-one" J. Org. Chem., 38(5) 1973 pp. 924-927.
I. P. Murina, et al., "Effect of Temperature on the Basicity of Certain Aliphatic-Aromatic Amino Alcohols" Bulletin of the Academy of Sciences of the USSR Division of Chemical Science 1976.
J. Am. Chem. Soc., 74 p. 1316 (1952).
J. S. New et al., "Applications of Lithium Aluminum Hydride in the Synthesis of Substituted Ethyl- and Propylamines" Synthesis (May 1983) pp. 388-389.
L. Angiolini, et al., "Stereochemistry of Mannich Bases-IT" Tetrahedron, vol. 25, pp. 4211-4216, 1969.
Lagidze et al., Chemical Abstracts, vol. 78, abstract 57901, 1972.
Olofsson et al., "Value of the Vinyloxycarbonyl Unit in Hydroxyl Protection: Application of the Synthesis of Nalorphine", Tetrahedron Letters, No. 18, 1977, pp. 1571-1574.
Organic Reactions, 35, Chapter 3, pp. 513-633 (1988).
P. Parimoo, et al., "New Compounds: Some Potential Chemotherapeutic Agents Derived from Aralkyl Ketones" Journal of Pharmaceutical Sciences, vol. 59, No. 7, Jul. 1970, pp. 1038-1041.
Parimmo et al., "New Compounds: Some Potential Chemotherapeutic Agents Derived from Aralkyl Ketones", J. Pharm. Sci., 59, pp. 1038-1041 (1970).
Potti et al., "Use of 3-Azabicyclo [3,2,1]octane in the Mannich Reaction", J. Pharm. Sci., 57, pp. 1487-1493 (1968).
Raffa et al., "Complementary and Synergistic Antinonciceptive Interaction between the Enantiomers of Tramadol", J. Pharmacol. Exptl. Ther., 267, pp. 331-340 (1993).
Raffa et al., "Opioid and Nonopioid Components Independently Contribute to the Mechanism of the Action of Tramadol . . . ", J. Pharmacol. Exptl. Ther., 260, pp. 275-285 (1992).
S. L. Spassov, et al., "Stereochemistry of Diastereomeric 3-Dialkylaminopropanols and O-Derivatives" Journal fuer Praktische Chemie, 1981.
Spassov et al., "Sterochemistry of Disasteromeric 3-Dialkylaminopropanols and O-Derivatives", J. Prakt. Chem., 323, pp. 793-800 (1981).
T. Kauffmann, et al., "Cyano(methyl)argentate: Spektroskopie, Selektivitaet als Methylierungsreagenzien, Vergleich mit anderen Methylsiber-Reagenzien" Chemische Berichte, 1992.
Thorberg et al., "Carbamate Ester Derivatives as Potential Prodrugs of the presynaptic Dopamine Autoreceptor Agonist . . . ", J. Med. Chem., 30, pp. 2008-2012 (1987).
Tramatoni, "Advances in the Chemistry of Mannich Bases", Synthesis, 1973, pp. 703-775.
V. Ghislandi, et al., "Preparation and Configuration of Racemic and Optically Active Analgesic Dialkylaminoalkylnaphthalenes" Chirality, vol. 6, No. 5, 1994.
Welch et al., "Reduction of Aryl Diethyl phosphates with Titanium Metal: A Method for Deoxygenation of Phenols", J. Org. Chem., 43, pp. 4797-4799 (1978).
Winterfeldt, "Applications of Diisobutylaluminium Hydride (DIBAH) and Triisobutylaluminium (TIBA) as Reducing Agents in Organic Synthesis", Synthesis, 1975, pp. 617-630.

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US8618177B2 (en) 2002-11-22 2013-12-31 Gruenenthal Gmbh Method of treating pain caused by inflammation
US10471079B2 (en) 2002-11-22 2019-11-12 Gruenenthal Gmbh Combination of selected analgesics and COX-II inhibitors
US20080247959A1 (en) * 2003-08-06 2008-10-09 Grunenthal Gmbh Form of administration secured against misuse
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US20070003616A1 (en) * 2003-12-24 2007-01-04 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US20080317854A1 (en) * 2004-04-22 2008-12-25 Grunenthal Gmbh Process for the production of an abuse-proofed solid dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US10675278B2 (en) 2005-02-04 2020-06-09 Grünenthal GmbH Crush resistant delayed-release dosage forms
US20060188447A1 (en) * 2005-02-04 2006-08-24 Elisabeth Arkenau-Maric Process for the production of an abuse-proofed dosage form
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US20080311187A1 (en) * 2005-02-04 2008-12-18 Grunenthal Gmbh Crush resistan delayed-release dosage form
US8722086B2 (en) 2007-03-07 2014-05-13 Gruenenthal Gmbh Dosage form with impeded abuse
US20100297229A1 (en) * 2007-11-23 2010-11-25 Nectid Inc. Tapentadol compositions
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9161917B2 (en) 2008-05-09 2015-10-20 Grünenthal GmbH Process for the preparation of a solid dosage form, in particular a tablet, for pharmaceutical use and process for the preparation of a precursor for a solid dosage form, in particular a tablet
US10206890B2 (en) 2008-09-05 2019-02-19 Gruenenthal Gmbh Pharmaceutical combination
US20100190752A1 (en) * 2008-09-05 2010-07-29 Gruenenthal Gmbh Pharmaceutical Combination
US9642801B2 (en) 2008-10-30 2017-05-09 Gruenenthal Gmbh And potent tapentadol dosage forms
WO2010096045A1 (en) 2008-10-30 2010-08-26 Nectid, Inc. Novel and potent tapentadol dosage forms
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US20110187017A1 (en) * 2010-02-03 2011-08-04 Grunenthal Gmbh Preparation of a powdery pharmaceutical composition by means of an extruder
WO2011107876A2 (en) 2010-03-05 2011-09-09 Actavis Group Ptc Ehf Improved resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol
WO2011128784A2 (en) 2010-04-05 2011-10-20 Actavis Group Ptc Ehf Novel process for preparing highly pure tapentadol or a pharmaceutically acceptable salt thereof
US9884022B2 (en) 2010-04-07 2018-02-06 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
WO2011124953A2 (en) 2010-04-07 2011-10-13 Lupin Limited Controlled release pharmaceutical compositions of tapentadol
EP3636629A1 (en) 2010-07-23 2020-04-15 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
EP3287447A1 (en) 2010-07-23 2018-02-28 Grünenthal GmbH Salts or co-crystals of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US8552219B2 (en) 2010-09-20 2013-10-08 Ind-Swift Laboratories Limited Process for preparing L-phenyl-3-dimethylaminopropane derivative
WO2012101649A1 (en) 2011-01-27 2012-08-02 Symed Labs Limited A novel stereospecific synthesis of (-) (2s,3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
WO2012146978A2 (en) 2011-04-28 2012-11-01 Actavis Group Ptc Ehf A novel process for the preparation of tapentadol or a pharmaceutically acceptable salt thereof
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
WO2015075678A1 (en) 2013-11-21 2015-05-28 Unimark Remedies Ltd. A novel process for the preparation of 1-phenyl-3-aminopropane derivatives
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
WO2016190766A1 (en) 2015-05-26 2016-12-01 Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa Compositions for use in treating parkinson's disease and related disorders
US9914695B2 (en) 2015-07-10 2018-03-13 Mallinckrodt Llc Two-step process for preparing 3-substituted phenylalkylamines
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2019238267A1 (en) 2018-06-15 2019-12-19 Pharmathen S.A. A novel process for the preparation of tapentadol

Also Published As

Publication number Publication date
DE4426245A1 (en) 1996-02-22
UA41345C2 (en) 2001-09-17
PL181169B1 (en) 2001-06-29
CA2154424C (en) 2008-04-15
IL113901A0 (en) 1995-08-31
AU685644B2 (en) 1998-01-22
CZ286441B6 (en) 2000-04-12
JP4846552B2 (en) 2011-12-28
UY23992A1 (en) 1995-08-02
ES2115298T3 (en) 1998-06-16
JP4034366B2 (en) 2008-01-16
JPH0899939A (en) 1996-04-16
CN1125221A (en) 1996-06-26
PL309734A1 (en) 1996-02-05
PE34896A1 (en) 1996-09-07
LU91793I2 (en) 2011-05-02
NZ272623A (en) 1996-02-27
US6248737B1 (en) 2001-06-19
HU9502146D0 (en) 1995-09-28
RU95113154A (en) 1997-06-27
GR3026326T3 (en) 1998-06-30
LTPA2011007I1 (en) 2018-08-10
JP2007084574A (en) 2007-04-05
CA2154424A1 (en) 1996-01-24
CZ190495A3 (en) 1996-05-15
MY114889A (en) 2003-02-28
EP0693475B1 (en) 1998-02-11
FI953523A0 (en) 1995-07-21
DE59501431D1 (en) 1998-03-19
SI0693475T1 (en) 1998-06-30
IL113901A (en) 1999-05-09
EP0693475A1 (en) 1996-01-24
US20020010178A1 (en) 2002-01-24
FI953523A (en) 1996-01-24
HU218481B (en) 2000-09-28
DE122011000007I1 (en) 2011-06-16
RU2150465C1 (en) 2000-06-10
HUT74100A (en) 1996-11-28
AU2713895A (en) 1996-02-08
BR9502390A (en) 1996-02-27
FR12C0016I2 (en) 2013-01-11
FR12C0016I1 (en) 2012-04-06
DK0693475T3 (en) 1998-09-23
FI114704B (en) 2004-12-15
KR100364465B1 (en) 2003-02-05
HK1005062A1 (en) 1998-12-18
ZA956118B (en) 1996-05-31
ATE163176T1 (en) 1998-02-15
CO4410179A1 (en) 1997-01-09
KR960004315A (en) 1996-02-23
US6344558B1 (en) 2002-02-05
CN1077566C (en) 2002-01-09

Similar Documents

Publication Publication Date Title
USRE39593E1 (en) 1-phenyl-3-dimethylaminopropane compounds with a pharmacological effects
JP4846750B2 (en) Dimethyl- (3-aryl-but-3-enyl) -amino compounds as pharmaceutically active substances
USRE37355E1 (en) 6-dimethylaminomethyl-1-phenyl-cyclohexane compounds as pharmaceutical active ingredients
CA2380857C (en) Substituted 2-dialkylaminoalkylbiphenyl derivatives
IL119864A (en) 1-phenyl-2-dimethylaminomethyl-cyclohexan-1-ol compounds, as pharmaceutically active compounds and their preparation
US6673794B2 (en) Substituted aminomethyl-phenyl-cyclohexane derivatives
US6890959B2 (en) Aminomethyl-phenyl-cyclohexanone derivatives
CA2378723A1 (en) 3-amino-2-benzyl-1-phenyl-propane derivatives
MXPA97001865A (en) Compounds of dimethyl- (3-aril-but-3-enil) -amino as active ingredients farmaceuti

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Free format text: PAYER NUMBER DE-ASSIGNED (ORIGINAL EVENT CODE: RMPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

CC Certificate of correction
FPAY Fee payment

Year of fee payment: 8

PTEF Application for a patent term extension

Free format text: PRODUCT NAME: TAPENTADOL HYDROCHLORIDE; REQUESTED FOR 1492 DAYS

Filing date: 20090115

Expiry date: 20180619

CC Certificate of correction
PTEG Grant of a patent term extension

Free format text: PRODUCT NAME: TAPENTADOL HYDROCHLORIDE

Filing date: 20090115

Expiry date: 20180619

FPAY Fee payment

Year of fee payment: 12

CC Certificate of correction